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Abstract 
 
SCOTT BRANTLEY: Translational Methods for Quantitative Prediction of Metabolic 
Herbal Product-Drug Interactions: Case Study with Milk Thistle 
 (Under the direction of Mary F. Paine, R.Ph., Ph. D.) 
The misperception that herbal products are safe has perpetuated multibillion 
dollar sales of these products, exposing the public to potentially harmful herb-drug 
interactions when constituents in the herbal supplement inhibit drug metabolizing 
enzymes. Regulation of herbal products is not as rigorous as drug products. 
Consequently, evaluation of inhibitory properties of an herbal product typically is not 
requested before marketing. Traditional drug-drug interaction evaluation methods often 
are inadequate to evaluate herbal product interaction liability due to the mixture of 
bioactive constituents, high inherent variability between batches and manufacturers, and 
limited pharmacokinetic knowledge of constituents. Milk thistle was selected as an 
exemplar herbal product due to high usage rates in patient populations, particularly the 
hepatically-impaired; availability of isolated, purified constituents; and disparate effects 
between previous clinical interaction studies. Initial screens of inhibitory activity against 
the clinically relevant drug metabolizing enzymes, cytochrome P450 (CYP) 2C9 and 
CYP3A4, prioritized milk thistle constituents for further evaluation. The main 
constituents, silybin A and silybin B, inhibited CYP2C9 in a reversible manner (Ki, 10 and 
4.8 µM, respectively) and CYP3A4 in an irreversible manner (KI, 110 and 89 µM, 
respectively). Incorporation of these in vitro kinetic parameters into a physiologically 
based pharmacokinetic (PBPK) model facilitated predictions of the interaction liability of 
milk thistle administration with FDA-recommended probe substrates of CYP2C9 
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(warfarin) and CYP3A4 (midazolam). Administration of large doses of the milk thistle 
product silibinin (1440 mg/day) was predicted to increase the peak concentration and 
systemic exposure of both warfarin and midazolam by roughly 5%. Proof-of-concept 
clinical evaluation of these silibinin-drug interactions confirmed the low interaction 
potential of the selected milk thistle product, as midazolam and warfarin exposure was 
increased modestly (9 and 13%, respectively). This mechanistic modeling and simulation 
approach facilitated prospective evaluation of interactions between a well-characterized 
herbal product and two widely used and clinically relevant probe substrates. This 
framework could be applied to other herbal products to predict the magnitude and 
likelihood of interactions with conventional drugs, guide pharmacotherapeutic decisions, 
and improve patient care. 
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Chapter 1 
 
Herb-Drug Interactions: 
Challenges and Opportunities for Improved Predictions 
 
Introduction 
Brief History of Natural Product Use for Medicinal Purposes. Healing plants 
gracing Neanderthal tombs and in the personal belongings of Ötzi the Iceman indicate 
that knowledge of the pharmacologic activity of herbs and other natural products 
predates written records (Tyler, 2000; Goldman, 2001). Exploitation of natural products 
for both therapeutic and nefarious purposes during the Greek and Roman empires was 
well-documented by Hippocrates and Galen (Forte and Raman, 2000). Perhaps the 
most famous early use of an herbal product for pharmacologic activity was the execution 
of Socrates by poison hemlock. By the early 19th century, scientific methods had 
advanced such that promotion of botanical products for healing was considered 
quackery (Winslow and Kroll, 1998). During the 1950s in the United States (US), herbal 
products began to regain popularity due to pharmaceutical tragedies such as 
thalidomide (Brownie, 2005). The herbal product market continued to grow in the 1960s, 
as consumers focused on the perceived lack of side effects and advances in scientific 
knowledge about natural products (Winslow and Kroll, 1998; Tyler, 2000). In 1974, the 
World Health Organization (WHO) began encouraging developing countries to 
supplement modern pharmacotherapy with traditional herbal medicines to fulfill needs 
unmet by conventional drugs (Winslow and Kroll, 1998). Herbal product sales in the US 
have continued to increase, reaching an estimated 5.1 billion dollars in 2010 (Blumenthal 
et al., 2011).   
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Prevalence of Co-administration of Herbal Products with Conventional 
Medications. An accurate estimate of the prevalence of herbal product usage and co-
administration with conventional medications is difficult, as consumers of herbal products 
seldom inform their health care providers (Gardiner et al., 2006). Since these products 
usually are self-administered as a means to treat or prevent the onset of a medical 
condition (Winslow and Kroll, 1998), concomitant intake with conventional medications 
can be expected (Gardiner et al., 2006; Kennedy et al., 2008). The National Health 
Interview Survey provides the most comprehensive evaluation of herbal product usage 
rates in the US, the most recent of which reported that approximately 20% of the US 
population acknowledges taking herbal products (Bent, 2008). This percentage may be 
even greater in patients with medical conditions such as chronic gastrointestinal 
disorders, insomnia, liver disease, chronic pain, depression, asthma, and women 
undergoing menopause (Gardiner et al., 2006). Of the survey responders who took an 
herbal product with conventional therapy, nearly 70% neglected to inform their health 
care providers (Gardiner et al., 2006; Kennedy et al., 2008). These practices raise 
concerns for adverse herb-drug interactions. 
Biochemical Mechanisms of Herb-Drug Interactions 
Inhibition of Drug Metabolizing Enzymes. Drug-mediated inhibition of drug 
metabolizing enzymes is the most common and most well-studied mechanism 
underlying drug-drug interactions (DDIs) (Wienkers and Heath, 2005). Enzyme inhibition 
can manifest as reversible or irreversible loss of activity. Reversible Inhibition. 
Competitive inhibition occurs when the ‘perpetrator’ drug or other xenobiotic binds to the 
active site of the enzyme and prevents the ‘victim’ drug from binding (Lin and Lu, 1998; 
Hollenberg, 2002) (Figure 1.1). The simplest case occurs when two substrates for the 
same enzyme are administered concomitantly, although the perpetrator drug need not 
be a substrate for the enzyme to demonstrate competitive inhibition (Kunze et al., 1991). 
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The functional consequence of competitive inhibition is that higher concentrations of the 
victim drug are needed to compete for the binding site, thereby increasing the 
concentration needed for half-maximal rate of metabolism (Km) while having no change 
in the maximal rate of metabolism (Vmax) (Lin and Lu, 1998; Hollenberg, 2002). 
Noncompetitive inhibition occurs when the perpetrator drug binds to a region of the 
enzyme that alters the ability to metabolize the victim drug (Figure 1.1). Since the 
perpetrator drug does not bind to the same site in the enzyme as the victim drug, 
increasing victim drug concentrations cannot compensate for the decrease in enzyme 
activity, leaving Km unchanged while lowering Vmax (Lin and Lu, 1998; Hollenberg, 2002). 
Uncompetitive inhibition occurs when the perpetrator drug binds to the enzyme-victim 
drug complex. Binding to the enzyme-substrate complex modulates both Vmax and Km 
(Lin and Lu, 1998; Hollenberg, 2002). For all of these situations, the return to basal 
enzyme activity relies purely on removal of the perpetrator drug from the system. 
Clinically, reversible inhibition manifests as an increase in the systemic exposure of the 
victim drug due to changes in clearance and/or bioavailability. Irreversible Inhibition. 
Inhibition perpetrated by compounds that do not associate and dissociate rapidly from 
the enzyme is termed time-dependent inhibition (TDI). Mechanism-based inhibition 
(MBI), often observed as TDI, is characterized by irreversible or quasi-irreversible 
noncovalent binding of a reactive metabolite to the enzyme (Grimm et al., 2009). The 
resultant binding can impede access to the active site, target the protein for proteasomal 
degradation, or alkylate the heme (Silverman and Daniel, 1995; Kalgutkar et al., 2007) 
(Figure 1.1). Comprehensive reviews detailing the mechanisms and clinical implications 
of irreversible inhibition have been published (Venkatakrishnan et al., 2007; Grimm et 
al., 2009). Due to the time-dependent nature, onset of irreversible inhibition in vivo can 
appear delayed from initial exposure to the perpetrator drug (Grimm et al., 2009). As 
with reversible inhibition, irreversible inhibition will lead to increased systemic exposure 
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of the victim drug. Unlike reversible inhibition, the interaction can persist following 
removal of the perpetrator drug because recovery of enzyme activity depends on de 
novo protein synthesis (Grimm et al., 2009).  
Inhibition of Protein-Mediated Flux. Compared to metabolism-based 
interactions, information about transporter-based interactions is limited, although the 
knowledge gap is narrowing (Han, 2011). Similar to drug metabolizing enzymes, 
transporters are susceptible to competitive and noncompetitive reversible inhibition due 
to perpetrator compounds blocking the drug binding site or causing a conformational 
change that decreases transport activity, respectively (Arnaud et al., 2010; Harper and 
Wright, 2013). Inhibitors of transporter activity can bind to regions of the transporter on 
either side of the lipid bilayer, creating scenarios in which inhibition may be either cis or 
trans in nature (Jutabha et al., 2010). In addition to these traditional modes of inhibition, 
the in vitro activity of drug transporters can be modulated by the composition of the cell 
membrane albeit clinical implications remain unknown (Annaba et al., 2008; Molina et 
al., 2008; Kis et al., 2009; Clay and Sharom, 2013). Inhibition of transporter activity in 
vivo can manifest as increased or decreased systemic exposure, and possibly altered 
organ exposure, of the victim drug depending on site of transporter expression and 
direction of flux. 
Induction of Drug Metabolizing Enzymes and Transporters. In addition to 
inhibition, DDIs can reflect increased enzyme or transporter expression. Common 
mechanisms of induction include increased gene transcription and stabilization of mRNA 
or active protein (Okey, 1990). The predominant mechanism for enzyme and transporter 
induction is a receptor-mediated increase in gene transcription due to perpetrator 
compounds activating one or more nuclear receptors (Hewitt et al., 2007). Binding of the 
perpetrator compound to the ligand binding domain of a nuclear receptor causes the 
activated receptor to bind to the xenobiotic response element located in the promoter 
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region of the gene (Figure 1.1). This process leads to increased transcription and 
subsequent translation of mRNA into enzyme protein (Lin and Lu, 1998). Induction of 
protein function also can reflect stabilization of mRNA or protein (Novak and Woodcroft, 
2000; Raucy et al., 2004; Kato et al., 2005; Menez et al., 2012). Enzyme induction 
manifests clinically as increased clearance or decreased bioavailability of the victim 
drug, whereas induction of transporter expression manifests as increased or decreased 
circulating concentrations of the victim drug depending upon the site of transporter 
expression. 
Challenges with Evaluating Herb-Drug Interactions 
Variability in Composition of Herbal Products. Unlike most drug products, 
herbal products frequently consist of multiple constituents that vary in composition, both 
between manufacturers and between batches from the same manufacturer. The putative 
bioactive agents in herbal products often are plant-derived secondary metabolites 
produced as part of normal plant metabolism or as a reaction to environmental stress 
(Rousseaux and Schachter, 2003). The relative concentration of each pharmacologically 
active compound may vary widely depending on growing conditions such as temperature 
and rainfall (Rousseaux and Schachter, 2003). A simple comparison to illustrate this 
variability is the extreme differences in wine quality and price between vineyards and 
vintages, even when produced from the same type of grapes (Paine and Oberlies, 
2007). Additional attention should be paid to the composition of herbal products to 
ensure reproducibility within studies and to permit comparisons between studies.   
Identification of Causative Agents. Modulation of drug metabolizing enzymes 
and transporters by herbal products can reflect interactions with one or more herbal 
product constituents. The net effect can result from additive, synergistic, or antagonistic 
interactions between multiple constituents (Efferth and Koch, 2011). Consequently, 
identification of the interacting agent(s) is needed to make accurate predictions of herb-
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drug interactions. Some herbal products, including St. John’s wort and milk thistle, are 
well-characterized, and individual constituents have been isolated in quantities sufficient 
for interaction screening (Obach, 2000; Weber et al., 2004; Lee et al., 2006b; Graf et al., 
2007; Tatsis et al., 2007; Brantley et al., 2010). Other techniques, such as bioactivity-
guided fractionation (Kim et al., 2011; Roth et al., 2011), can be used to elucidate the 
causative agents from herbal products.  
Pharmacokinetic Disposition of Causative Constituents. As with 
conventional DDI predictions, knowledge of the pharmacokinetic disposition of the 
perpetrator herbal product is needed to make accurate predictions of herb-drug 
interactions. Herbal products with extensive clearance in the liver and small intestine are 
still marketed (e.g., resveratrol) whereas traditional pharmaceutical compounds with 
these characteristics typically are excluded from further development. This extensive 
elimination or low bioavailability results in low circulating levels of the ‘parent’ herbal 
product. Another consequence of a high pre-systemic clearance is that the systemic 
concentration of the natural product perpetrator, if measurable, may be a less-than-ideal 
surrogate for the concentration at the site of interaction. However, upon oral dosing, high 
exposure of the perpetrator (parent and/or metabolite) during first-pass can inhibit 
intestinal extraction or first-pass hepatic extraction of victim drugs. With respect to 
induction, concentrations of the parent and metabolite should be monitored with chronic 
exposure.  
Regulatory Perspectives on Herbal Products 
While regulatory agencies often require full characterization of the drug 
interaction liability of conventional pharmaceutical agents prior to market approval, 
perspectives vary regarding evaluation of herbal products. Herbal product usage is 
woven into cultural traditions, rendering establishment of regulatory precedent difficult 
(Rousseaux and Schachter, 2003). Although the primary responsibility of regulatory 
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agencies is the safety of the general public, cultural and traditional use of herbal 
products limits the ability of regulatory agencies to restrict herbal pharmacotherapy. 
Regulatory agencies have developed different methods for addressing the delicate 
balance between availability and safety. Cultural and economic factors often dictate the 
final course of action. Regulatory views on herbal products in the US, the European 
Union, and Canada are summarized below. 
Regulation in the United States. The Food and Drug Administration (FDA) 
received jurisdiction to regulate herbal products under the Dietary Supplement Health 
and Education Act (DSHEA) of 1994 (Table 1.1). This Act provides the legal definition of 
dietary supplements, including herbal products, and dictates that such supplements be 
regulated as foods rather than drugs. Under this classification, dietary supplements are 
presumed to be safe “within a broad range of intake”. Herbal products marketed after 
passage of the DSHEA are subject to a pre-market review of safety data, whereas 
products sold prior to passage of the DSHEA are exempt (de Lima Toccafondo Vieira 
and Huang, 2012). Contrary to conventional drugs, the burden of proof is on the FDA to 
demonstrate that these products pose “significant or unreasonable risk” before removal 
from the market (Brownie, 2005). Supplement manufacturers are prohibited from making 
claims about the ability of herbal products to diagnose, mitigate, treat, cure, or prevent a 
specific disease or class of diseases without undergoing evaluation as conventional 
drugs (DSHEA). For herbal products with established drug interaction liability, the FDA 
requires mention of potential herb-drug interactions in the prescribing information of 
victim drugs but not in the label, of the perpetrator herbal product. 
Regulation in the European Union. Herbal product usage varies widely among 
countries of the European Union (EU), leading to differences in regulatory classifications 
in individual countries. Germany and France have a long history of herbal product use 
and report a combined sales of 3.2 billion dollars in 2003 (De Smet, 2005). In contrast, 
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Portugal, Hungary, Ireland, Slovakia, Finland, and Norway have less developed histories 
of herbal product use, with less than 0.15 billion dollars in combined sales in 2003 (De 
Smet, 2005). Initial attempts in 2002 to harmonize these disparate views generated safe 
lists of vitamins and minerals, but national rules for other nutrients and dietary 
supplements remained intact (Directive 2002/46/EC). With regulation of herbal products 
left to the agencies in each member country, there were 27 different national 
perspectives regarding regulation of herbal products (Table 1.1). The second attempt in 
2004 in market harmonization created a category termed ‘traditional herbal medicinal 
products’ (THMP) and has provided some harmonization at the national level for 
medicinal products with traditional or historical uses (Silano et al., 2011). Market 
authorization of a product as a THMP requires that the product be on the market for at 
least 30 years, 15 of which must be in an EU member country (Silano et al., 2011). 
Registration under this directive requires more information than the US FDA requires for 
herbal products but less information than the US FDA or European Medicines Agency 
(EMA) require for conventional drugs. Herbal product manufactures were given until 
April 2011 to register a product for consideration as an herbal medicine (Silano et al., 
2011). Although market harmonization has begun, decisions as to market authorization 
are still left to individual member countries. This incomplete harmonization creates an 
environment where an herbal product can be marketed as a food supplement in one 
country, a THMP in another country, and prohibited in a third country (Silano et al., 
2011).  
Regulation in Canada. Herbal products are regulated by the Natural Health 
Product Directorate (NHPD) branch of Health Canada (Table 1.1). The role of the NHPD 
is to “ensure that Canadians have ready access to natural health products that are safe, 
effective and of high quality while respecting freedom of choice and philosophical and 
cultural diversity” (Health Canada, 2006). Unlike in the US and the EU, herbal product 
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manufacturers must provide evidence to support both the safety and efficacy of a 
product before market approval. As part of the safety information required for approval, 
manufacturers must provide a safety summary report containing information regarding 
the interaction potential with other medicinal products, foods, or standardized laboratory 
tests (Health Canada, 2006). Upon approval, herbal products receive a product license 
and identification number. All approved herbal products are required to meet strict 
labeling requirements. Moreover, removal of an herbal product from the market is less 
cumbersome than in the US. The Health Minister can suspend sales of natural health 
products if a manufacturer does not provide requested safety information or if the 
Minister has reasonable grounds to believe that the product is not complying with other 
provisions of NHPD regulations. 
Herb-Drug Interaction Predictions 
 Current Prediction Strategies. Compared to qualitative descriptions of herb-
drug interactions, prospective quantitative predictions of these interactions are at best in 
embryonic stages. Since herbal products are not regulated in the same manner as 
drugs, assessment of herb-drug interaction liability often is not requested prior to 
marketing. As such, herb-drug interaction studies typically are initiated only upon receipt 
of case reports documenting a putative interaction or in vitro experiments highlighting a 
potential interaction. Shifting the evaluation paradigm to prospective predictions would 
allow consumers and healthcare providers to make informed decisions regarding the 
addition of herbal products to conventional drug regimens. 
Limitations of Current Prediction Strategies. Current herb-drug interaction 
predictions are limited due to the aforementioned challenges in evaluating drug 
interaction liability of herbal products. Natural products typically are complex mixtures of 
potentially bioactive compounds, any of which may interact with drug metabolizing 
enzymes or transporters. Static prediction equations are not amenable to complex 
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interactions due to multiple constituents; consequently, more sophisticated prediction 
strategies, such as physiologically-based pharmacokinetic modeling (PBPK), are 
preferable (US FDA, 2012; Huang, 2012). Summarized below are current approaches 
for evaluating the DDI potential of conventional pharmaceutical compounds that can be 
applied to natural products.  Information from in vitro experiments, pre-clinical and 
clinical studies, and in silico simulations can be used to assess herb-drug interaction 
potential.  The herb-drug interaction of milk thistle was evaluated using these techniques 
and is presented as a case study.  Systematic generation of herb-drug interaction 
information would help predict, mitigate, and ideally prevent, adverse herb-drug 
interactions in the general population. 
Evaluation of HDI using in vitro systems. In vitro systems are foundational 
tools used to estimate the contribution of drug metabolizing enzymes and transporters to 
the disposition of an herbal product.  Moreover, results derived from in vitro experiments 
can be used to predict quantitatively the potential for a DDI.  Common in vitro systems to 
assess drug metabolism include microsomal fractions, recombinant enzymes, and 
hepatocytes. Transport activity typically is determined using cell lines such as Caco-2 or 
Madin-Darby canine kidney (MDCK) cells, where bi-directional transport can be 
measured, or cells overexpressing particular transporters (Cvetkovic et al., 1999; Cui et 
al., 2001; Troutman and Thakker, 2003; Kindla et al., 2011; Kimoto et al., 2013; Kock et 
al., 2013). To estimate biliary transport, sandwich-cultured hepatocytes can be used to 
mimic 3-dimensional hepatic architecture (Liu et al., 1999; Annaert et al., 2001).  
Refinement of these systems continues to provide improved estimates of drug 
disposition. 
Human-derived microsomes or recombinant enzymes are used to determine both 
the potency and mechanism of enzyme inhibition. Details about the appropriate conduct 
of these studies are described elsewhere (Bjornsson et al., 2003; Grimm et al., 2009). 
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Cell lines are used to determine whether the drug can inhibit transport of probe 
substrates such as digoxin (P-glycoprotein) or statins (breast cancer resistance protein 
[BCRP] and organic anion transporting polypeptide [OATP]). The likelihood of observing 
inhibition in vivo can be estimated by using the in vitro-determined kinetic parameters, as 
well as observed systemic concentrations (if available). A caveat is that circulating 
concentrations may not represent the DDI liability during first-pass metabolism.    
Unlike inhibition experiments that can rely on human liver microsomes, induction 
experiments must rely on intact cells. Determination of induction is dependent upon the 
measurement of mRNA or protein expression for both metabolic enzymes and 
transporters. The induction response of immortalized cells (e.g., Caco-2 or HepG2) may 
not be as robust as in human hepatocytes because the immortalization process may 
have decreased or altered expression of particular transcription factors or nuclear 
receptors.   
Evalution of HDI in Pre-Clinical Animal Models. The use of animal models is a 
critical step in the drug development process. Although predictions can be made using in 
vitro data, several key characteristics of drug disposition can only be determined in vivo, 
namely the relative contribution of metabolic and excretory routes to total drug 
clearance. Moreover, mass-balance and the percent contribution of an enzymatic 
pathway to overall elimination can only be estimated using in vivo data. Without in vivo 
data, the appropriateness of PBPK models cannot be assessed. Information derived 
from properly designed pharmacokinetic studies can be used to develop or refine PBPK 
models. Thus, in addition to helping determine bioavailability and tissue localization of a 
drug, animals can provide an estimate of exposure to metabolites following 
administration of the parent drug. In general, in vitro data are scaled to determine DDI 
liability and whether human in vivo DDI studies should be conducted. In some instances, 
animals can provide mechanistic insight into the DDI that is not amenable to with a 
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human study. A major disadvantage of the use of animal models is the possibility of 
discordant metabolic and transport pathways compared to humans. Not surprisingly, 
animals have enzyme or transporter orthologs that differ in tissue expression or 
substrate specificity (Martignoni et al., 2006; Chu et al., 2013).   
Clinical Studies. Best practices for appropriate conduct of clinical herb-drug 
interaction studies closely resemble those for food-drug interaction studies as reviewed 
previously (Won et al., 2012). As with food-drug interaction studies, the critical step in 
herb-drug interaction studies is quantification of the putative perpetrator compound(s) in 
the herbal product. Recently, the Consolidated Standards of Reporting Trials 
(CONSORT) checklist was updated to include herbal medicinal products (Gagnier et al., 
2006). The interventions section of this checklist was extended to highlight the 
importance of the name, characteristics, dosage regimen, quantitative description, and 
qualitative testing of the herbal product. Although this checklist is meant to allow quality 
reporting of trials involving herbal medicines, the major emphasis of this update also is 
applicable to interaction studies. Ideally, with increased awareness, herb-drug interaction 
studies will more resemble those for DDIs, guidances for which have been discussed 
extensively elsewhere (EMA, 2012; US FDA, 2012). 
In Silico Simulation Software Packages. Modeling and simulation-based 
strategies have become useful tools in DDI predictions. PBPK models in particular are 
emphasized in regulatory recommendations for (1) predicting the likelihood and 
magnitude of drug interactions and (2) providing greater insight into causes of 
uncertainty and variability in evaluation of DDIs (EMA, 2012; US FDA, 2012). Several 
commercial software packages that facilitate model development are available. PBPK 
models can be developed using differential equation solving software packages such as 
MATLAB® Simulink®, Berkeley MadonnaTM, and acslX. These programs do not contain 
pre-defined model structures or differential equations, thus leaving the model complexity 
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and flexibility dependent upon the ambition and coding experience of the modeler. PBPK 
modeling software such as Simcyp®, PK-Sim®, GastroPlus®, and MATLAB® SimBiology 
provide template model structures at the expense of full customization. Regardless of 
the software package chosen, PBPK models require more parameters than other 
modeling strategies. Compound-independent physiologic parameters such as organ 
weights and blood flows can be obtained from the literature (Brown et al., 1997; 
Boecker, 2003). Compound-dependent parameters such as tissue partition coefficients, 
absorption rates, and metabolic clearances can be determined from in vitro and animal 
experiments or estimated from physicochemical parameters of the natural product 
(Poulin and Theil, 2000; Rodgers and Rowland, 2007). PBPK models of victim and 
perpetrator compounds can be linked through relevant interaction mechanisms, such as 
reversible or time-dependent inhibition, to simulate herb-drug interactions (US FDA, 
2012). Comprehensive reviews of PBPK model software and applications have been 
published (Khalil and Laer, 2011; Rowland et al., 2011; Zhao et al., 2012). 
Case Study: Milk Thistle 
Herbal Product Identification and Usage. Milk thistle (Silybum marianum (L.) 
Gaertn.) is a member of the Asteraceae plant family whose use in treating hepatic 
disorders was documented by Pliny the Elder (AD 23-79) (Kroll et al., 2007; Post-White 
et al., 2007). More recently, extracts from the plant have shown promise in pre-clinical 
studies for treatment of hepatic disorders such as acute hepatitis, chronic hepatitis B, 
and hepatitis C infections (Wei et al., 2012). However, the clinical efficacy in treating 
these disorders has been limited (Gordon et al., 2006; Rambaldi et al., 2007; Seeff et al., 
2008; El-Kamary et al., 2009; Payer et al., 2010; Fried et al., 2012). In addition to 
treatment for liver disease, milk thistle extracts may mitigate drug-induced hepatotoxicity 
from chemotherapeutic agents used for childhood acute lymphoblastic leukemia (Ladas 
et al., 2010) and acute myelogenous leukemia (McBride et al., 2012). Milk thistle 
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extracts and chemical derivatives are used in the treatment of fulminant liver failure 
caused by death cap (Amanita phalloides) mushroom poisoning (Mengs et al., 2012). 
Although milk thistle research remains focused on liver ailments, recent research has 
highlighted potential uses for treatment of obsessive compulsive disorder (Sayyah et al., 
2010; Camfield et al., 2011), type II diabetes (Huseini et al., 2006), beta-thalassemia 
major (Gharagozloo et al., 2009), influenza A (Song and Choi, 2011), and prostate 
cancer chemoprevention (Agarwal et al., 2006; Flaig et al., 2007; Vidlar et al., 2010). 
Continuous use of milk thistle products for nearly 2000 years in treating various ailments 
suggests putative efficacy; however, clinical evidence remains limited. 
Extracts from milk thistle are commercially available with varying degrees of 
purification and chemical modification. Crude milk thistle extract is available and often is 
standardized to contain 65-80% silymarin and 20-35% fatty acids (Kroll et al., 2007). 
Silymarin is a mixture of at least seven flavonolignans and the flavonoid taxifolin (Figure 
1.2). Flavonolignans are formed by conjugation of taxifolin with coniferyl alcohol to 
create structural isomers with the same molecular weight, permitting rudimentary 
calculations of silymarin concentrations in molar units (Kim et al., 2003a; Davis-Searles 
et al., 2005; Graf et al., 2007). Although the abundance of flavonolignans varies among 
different preparations, the most prevalent flavonolignans usually are the diastereoisomer 
pair silybin A and silybin B (Davis-Searles et al., 2005; Wen et al., 2008). Silychristin and 
silidianin also are relatively abundant in most silymarin preparations (Davis-Searles et 
al., 2005; Wen et al., 2008). The diastereoisomeric pair isosilybin A and isosilybin B, as 
well as isosilychristin, are relatively scarce in most preparations (Davis-Searles et al., 
2005; Wen et al., 2008). Semi-purification of the crude extract yields a roughly 1:1 
mixture of silybin A and silybin B, which is termed silibinin. The semi-purified mixture of 
isosilybin A and isosilybin B (isosilibinin) has been used in pre-clinical research but is not 
yet available as a commercial preparation (Kroll et al., 2007). Chemical modification of 
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silybin A and silybin B to increase water solubility for administration as an intravenous 
formulation led to generation of the dihemisuccinate ester derivative, Legalon SIL 
(Mengs et al., 2012). Since milk thistle products are purified from natural sources, large 
differences exist in the relative composition of the various constituents. With the 
exception of the prescription preparations available in some countries, there is no 
regulatory requirement for consistency between products. Consequently, high batch-to-
batch and manufacturer-to-manufacturer variability in the relative abundance of milk 
thistle constituents is commonplace (Davis-Searles et al., 2005; Lee et al., 2006a; Wen 
et al., 2008). 
Metabolism of Milk Thistle Constituents. Investigations into the metabolic 
clearance of milk thistle flavonolignans have focused on the oxidative and conjugative 
metabolism of silibinin. The major oxidative metabolite of silibinin is an O-demethyl 
product generated by cytochrome P450 (CYP) 2C8 in human liver microsomes 
(Gunaratna and Zhang, 2003; Jancova et al., 2007). All milk thistle flavonolignans share 
the methoxy moiety, part of the coniferyl alcohol, which does not participate in the 
conjugation to taxifolin. Thus, oxidation of this moiety could be similar among all 
flavonolignans. Formation of the mono- and di-methylated products was much lower 
than O-demethyl product upon oxidation of silibinin (Gunaratna and Zhang, 2003). Milk 
thistle flavonolignans are conjugated extensively by uridine 5'-diphospho-
glucuronosyltransferases (UGTs). In human liver microsomes and hepatocytes, 
conjugation of silybin A and silybin B demonstrated preferential formation of the 7-O-
glucuronide (Jancova et al., 2011). Among recombinant UGTs, UGT1A1, -1A3, -1A8, 
and -1A10 contributed to silybin A and silybin B metabolism (Jancova et al., 2011). 
Pharmacokinetics of Milk Thistle Constituents. Following oral administration, 
milk thistle flavonolignans are absorbed rapidly, with maximal systemic concentrations 
achieved in less than two hours (Weyhenmeyer et al., 1992; Kim et al., 2003b; Wen et 
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al., 2008). As with many natural products based on a flavonoid scaffold, milk thistle 
bioavailability is low due to extensive pre-systemic conjugation by UGTs and 
sulfotransferases (SULTs) (Wen et al., 2008). Upon reaching the systemic circulation, 
parent flavonolignan clearance is rapid, with a terminal elimination half-life of less than 4 
hours (Kim et al., 2003b; Wen et al., 2008). Systemic exposure to conjugated 
flavonolignans is consistently higher than parent flavonolignans. For example, exposure 
to conjugated isosilybin B was nearly 24-fold higher than that of the unconjugated parent 
in healthy volunteers following a 600 mg milk thistle dose (Wen et al., 2008). 
Subsequent to conjugation, flavonolignans are transported into the bile (Schandalik et 
al., 1992), and deconjugation in the intestine permits reabsorption and enterohepatic 
recirculation of flavonolignans. Renal clearance of total (unconjugated plus conjugated) 
silybin A and silybin B is roughly 30 mL/min, with approximately 5% of the dose 
eliminated in the urine as conjugates (Weyhenmeyer et al., 1992). Compared to healthy 
volunteers, Hepatitis C and nonalcoholic fatty liver disease patients have increased 
exposure to milk thistle flavonolignans and conjugated flavonolignans (Schrieber et al., 
2008). Patients with extrahepatic biliary obstruction show increased systemic exposure 
to total, but not parent silibinin. This observation suggests that biliary excretion is rate-
limiting for the clearance of conjugated metabolites but not the parent flavonolignans 
(Schandalik and Perucca, 1994). 
Inhibition of Drug Metabolizing Enzymes. The inhibitory effects of milk thistle 
extracts and constituents depend on the preparation as well as the enzyme system and 
substrate tested. Silibinin has been shown to be a mechanism-based inhibitor of 
CYP2C9 and CYP3A4 in expressed enzymes (Sridar et al., 2004) or a reversible 
inhibitor of CYP2C9 (Jancova et al., 2007; Brantley et al., 2010) and CYP3A4 (Zuber et 
al., 2002; Jancova et al., 2007) in human liver microsomes (Table 1.2). The inhibitory 
potency of silibinin towards CYP3A4 appears to be substrate-dependent, with higher 
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potency towards oxidation of nifedipine (Beckmann-Knopp et al., 2000; Zuber et al., 
2002) and testosterone (Jancova et al., 2007) than erythromycin (Beckmann-Knopp et 
al., 2000). Although silibinin constitutes nearly 50% of silymarin, silymarin extract is a 
more potent inhibitor of CYP2C19-mediated (S)-mephenytoin 4’-hydroxylation than 
silibinin (Ki = 2.2 µM vs. IC50 > 200 µM) (Beckmann-Knopp et al., 2000). Compared to 
the cytochromes P450, inhibition of UGT activity by milk thistle constituents is less 
studied. Silibinin demonstrated potent inhibition of recombinant UGT1A1-mediated 7-
hydroxy-4-trifluoromethylcoumarin metabolism (IC50 = 1.4 µM) (Sridar et al., 2004), 
whereas milk thistle extract inhibited UGT1A-mediated estradiol metabolism in human 
liver microsomes, with an IC50 of nearly 40 µM (Mohamed et al., 2010). 
Modulation of Drug Metabolizing Enzymes and Transporters in Cell 
Systems. The effect of milk thistle extracts on enzyme expression and activity in intact 
cell systems differs depending on the extract, cell system, and probe substrate 
examined. Silymarin was shown to decrease CYP3A4-mediated testosterone 
metabolism by 50% relative to vehicle control in human hepatocytes (Venkataramanan 
et al., 2000). Silibinin had no effect on cortisol metabolism in CYP3A4-expressing Caco-
2 cells (Patel et al., 2004) (Table 1.3). The effect of milk thistle on P-glycoprotein (P-gp) 
was even more variable than on drug metabolizing enzymes. Silibinin decreased P-gp 
expression by nearly 70% in Caco-2 cells (Budzinski et al., 2007) but had no effect on 
ritonavir transport in either Caco-2 or MDCK cells (Patel et al., 2004). In contrast, 
silymarin inhibited the P-gp-mediated transport of digoxin and vinblastine in Caco-2 cells 
(Zhang and Morris, 2003a) and of daunomycin in MDA435/LCC6 cells (Zhang and 
Morris, 2003b). In addition to inhibition of efflux transporters, silymarin inhibited uptake of 
estradiol-17B-glucuronide and estrone-3-sulfate mediated by organic anion-transporting 
polypeptides (OATPs) 1B1, 1B3, and 2B1 in xenopus oocytes and HEK cells (Deng et 
al., 2008; Köck et al., 2013).    
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Milk Thistle-Drug Interaction Predictions. To date, no studies have 
investigated the drug interaction liability of milk thistle using in silico modeling and 
simulation. Of the reported in vitro studies that mention herb-drug interaction with milk 
thistle products, the majority urge caution when milk thistle products are co-administered 
with sensitive victim drugs due to unknown interaction liability (Beckmann-Knopp et al., 
2000; Venkataramanan et al., 2000; Nguyen et al., 2003; Sridar et al., 2004; Etheridge et 
al., 2007; Deng et al., 2008; Brantley et al., 2010; Mohamed et al., 2010; Doehmer et al., 
2011; Mohamed and Frye, 2011). The remaining studies dismiss interaction liability due 
to the low plasma concentrations of milk thistle constituents or low inhibitory potency 
(Zuber et al., 2002; Jancova et al., 2007; Doehmer et al., 2008). Taken together, 
accurate predictions of herb-drug interaction liability remain elusive. 
Pre-Clinical Milk Thistle-Drug Interaction Studies. Silymarin increased 
resperidone exposure and maximal plasma concentration in rats following repeated oral 
doses, consistent with inhibition of P-gp  (Lee et al., 2013) (Table 1.4). Silibinin also 
increased systemic exposure to tamoxifen in rats in a dose-dependent manner (Kim et 
al., 2010). Unlike for humans, tamoxifen disposition in the rat has not been defined. 
Although the exact mechanism for this increased exposure could not be identified, the 
net effect could reflect inhibition of one or more rodent orthologs of the relevant human 
enzymes and transporters.  
Clinical Milk Thistle-Drug Interaction Studies. The clinical interaction liability 
of milk thistle products has been examined over the past decade (Table 1.5). Apart from 
increased exposure to losartan and talinolol (Han et al., 2009b), the majority of studies 
reported no clinically significant interactions. Limitations in study design and lack of 
information about the composition of the milk thistle preparations may have hampered 
detection of a clinically significant interaction. 
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Relatively low doses of silymarin (140 mg TID) inhibited the CYP2C9- and 
CYP3A4-mediated hepatic clearance of losartan, leading to a doubling in losartan 
exposure in CYP2C9*1/*1 subjects. Individuals carrying the CYP2C9*3 allele (reduced 
activity allele of CYP2C9) experienced an increase in maximal losartan concentrations 
without a significant increase in systemic exposure (Han et al., 2009b). Losartan is a 
prodrug that is converted to the active metabolite E-3174 by CYP2C9. Consistent with a 
decrease in formation clearance by CYP2C9, exposure to the active metabolite was 
decreased following milk thistle administration. The decrease was relatively modest 
(~15%), indicating limited clinical importance of this interaction (Han et al., 2009b). 
However, clinically important interactions with larger doses of milk thistle or a more 
sensitive CYP2C9 substrate cannot be dismissed.    
Studies of the interaction between milk thistle and HIV-protease inhibitors 
demonstrated no interaction; however, extrapolations of the results are limited due to 
study design considerations. Long-term administration of milk thistle products (2-4 
weeks) at various doses (160-450 mg TID) did not lead to significant changes in 
indinavir exposure or maximal concentration (Piscitelli et al., 2002; DiCenzo et al., 2003; 
Mills et al., 2005). Plasma exposure and maximal concentration of indinavir decreased  
following milk thistle administration (by 8.8 and 9.2%, respectively), which is inconsistent 
with inhibition of CYP3A4 (Piscitelli et al., 2002). Interaction studies with indinavir are not 
amenable to fixed sequence design because indinavir alone exhibits significant 
decreases in systemic exposure following long-term treatment. Compared to baseline 
conditions, healthy volunteers showed a 40% decrease in exposure 7 days after a 28-
day cycle of indinavir (Mills et al., 2005). Indinavir also is a potent CYP3A inhibitor, which 
would decrease study sensitivity to detect mild or moderate inhibition of CYP3A. As with 
indinavir, milk thistle administration with ritonavir or darunavir was not associated with a 
significant change in drug exposure in HIV-infected patients (Molto et al., 2012). 
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Ritonavir also is a potent CYP3A inhibitor, which would decrease greatly the sensitivity 
to detect further enzyme inhibition.    
Summary and Perspectives 
 Herbal product usage likely will continue to increase, in part due to attempts by 
consumers to decrease medical costs through self-diagnosis and treatment. In parallel, 
the prevalence of concomitant administration of herbal products with conventional 
medications will increase. Despite the mounting likelihood of herb-drug interactions, 
there remains no standard system for evaluating herb-drug interaction liability. The 
complex nature and high compositional variability of herbal products make evaluation of 
herb-drug interactions more challenging than DDIs. Moreover, regulatory agencies 
request varying degrees of pre-market safety information regarding herbal products. 
Taken together, there is an unprecedented opportunity to develop a framework for 
improving predictions of herb-drug interactions. The strategies to evaluate conventional 
DDIs, such as integrating in vitro parameters and the pharmacokinetics of individual 
herbal product constituents into PBPK interaction models, should be applied to herbal 
products in a prospective manner. Adoption of these strategies may streamline safety 
assessment of natural products, assist in the management of herb-drug interactions, and 
ultimately promote the safe use of herbal products. 
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Project Overview 
 
The risk of untoward interactions between herbal products and conventional 
drugs is increasing as a function of the increasing usage of herbal products. Despite the 
increased risk, there remains no standard system for evaluating herb-drug interaction 
potential. Complicating this evaluation is the large compositional variability and 
unidentified constituents in herbal products. Advances in isolation and purification 
techniques allow testing of the interaction potential of individual constituents using 
standard in vitro methods. Incorporation of the recovered kinetic parameters into a 
physiologically based pharmacokinetic (PBPK) model will allow improved herb-drug 
interaction predictions. Extrapolation of this methodology will facilitate improved 
decisions regarding the addition of herbal products to conventional pharmacology. 
The goal of this dissertation project was to evaluate the potential of an herbal 
product-drug interaction using a PBPK modeling approach and milk thistle as an 
exemplar herbal product. The central hypothesis was that integrating the in vitro 
inhibition kinetics of individual milk thistle constituents into a PBPK interaction model will 
enable accurate predictions of herb-drug interactions. The central hypothesis was tested 
with the subsequent specific aims: 
Specific Aim 1: Determine the interaction potential of milk thistle constituents and 
commercial preparations using in vitro screens of CYP inhibition. 
Hypothesis: Human liver- and intestine-derived systems can be used to determine the 
inhibitory potency of individual milk thistle constituents, as well as commercial 
preparations, on key drug metabolizing enzymes. 
1A. Determine the reversible and/or mechanism-based inhibition kinetics of milk 
thistle commercial preparations and individual constituents on CYP2C9 activity 
using human-derived microsomes and recombinant enzymes. 
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1B. Determine the reversible and/or mechanism-based inhibition kinetics of 
commercially available milk thistle preparations and individual constituents on 
CYP3A4/5 using human-derived microsomes and recombinant enzymes. 
Specific Aim 2: Predict the clinical impact of co-administration of a milk thistle 
product with prototypic cytochrome P450 probe substrates. 
Hypothesis: PBPK interaction models can accurately predict the likelihood and 
magnitude of an herbal product-drug interaction. 
2A. Develop a PBPK model for the cytochrome P450 probe substrates (S)-warfarin 
(CYP2C9) and midazolam (CYP3A4/5).  
2B. Develop a PBPK model for selected milk thistle constituents using parameters 
obtained from Aim 1. 
2C. Develop a PBPK interaction model using parameters obtained from Aim 1 and 
integrating the models created in Aim 2A and 2B. 
Specific Aim 3: Evaluate model predictions via a proof-of-concept clinical study. 
Hypothesis: Predictions of herbal product-drug interactions can be validated using a 
proof-of-concept clinical study. 
3A. Determine the relative composition of a selected milk thistle product with regard 
to the inhibitory constituents identified in Aim 1. 
3B. Evaluate the accuracy of the PBPK model predictions via a clinical study. 
The purpose of this dissertation was to determine if PBPK interaction models can 
facilitate predictions of the likelihood and magnitude of herb -drug interactions through 
identification of drug interaction perpetrators contained in the exemplar herbal product 
milk thistle and simulating the interaction potential of those constituents on the 
metabolism of victim drugs. This novel framework will provide a streamlined approach to 
study herbal product-drug interactions, and has the potential to predict drug interactions 
from current and future combinations of herbal products and victim drugs.  
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Legends to Figures 
 
Figure 1.1. Biochemical mechanisms of metabolic herb-drug interactions. In the 
absence of herbal constituents, drug molecules are metabolized by enzymes. 
Competitive inhibition by an herbal constituent prevents the drug molecule from binding 
to the active site of the enzyme. Noncompetitive inhibition by an herbal constituent 
decreases the catalytic activity of the drug metabolizing enzyme without interfering with 
the binding of drug molecule to the enzyme active site. Uncompetitive inhibition by an 
herbal constituent modulates apparent affinity and activity by binding to the enzyme-drug 
molecule complex. Irreversible inhibition occurs when the herbal constituent mediates 
enzymatic degradation. Enzyme induction occurs when herbal constituents bind to 
nuclear receptors and activate mRNA expression and protein synthesis.  
Figure 1.2. Chemical structures of milk thistle constituents.  
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Table 1.1 Key regulatory guidance points 
Guidance Points Country / Union 
 United States European Union Canada 
Regulatory 
Authorization 
Dietary Supplement Health 
and Education Act of 1994 
Directive 2002/46/EC 
Directive 2004/24/EC 
Natural Health Products 
Regulations 
Regulatory Agency 
US Food and Drug 
Administration  
European Medicines Agency 
(EMA) 
Committee on Herbal 
Medicinal Products  
Health Canada (Natural 
Health Product Directorate 
branch) 
Classifications Dietary Supplements 
Traditional Plant Food 
Supplement 
Traditional Herbal Medicinal 
Products  
Natural Health Product  
Safety data required 
pre-marketing 
Yes for ingredients introduced 
after 1994 
Extent of required data 
dependent on classification 
and member country 
competent authority 
Yes for all products 
Adverse Event 
Reporting 
Manufacturers are required to 
inform FDA of any adverse 
events reported directly to the 
manufacturer 
Pharmacovigilance 
maintained by EMA, 
manufacturers, and health 
care practitioners 
Manufacturers required to 
monitor adverse events 
and report serious adverse 
events to Health Canada 
Requirement of 
Good Manufacturing 
Practices 
Modeled after food GMP 
Required for all manufacturers 
in 2010 
Required for all products Required for all products 
Label Requirements 
 Name of each ingredient 
 Quantity of each 
ingredient 
 Contact information for 
the manufacturer 
 The statement “Not 
evaluated by the FDA. Not 
intended to diagnose, 
treat, cure, or prevent any 
disease” 
 Exact centesimal product 
formula 
 Exact nature of 
plants/extracts present 
 Conditions of use 
 Possible interactions with 
drugs and/or foods 
 Common and proper 
name of each 
medicinal ingredient 
 Quantity of each 
medicinal ingredient 
 Recommended use, 
dose, route of 
administration, 
duration of use 
 Risk information 
 Lot number and expiry 
date 
 Description of source 
material for each 
medicinal ingredient 
Permissible Health 
Claims 
Characterize the means by 
which the dietary supplement 
acts to maintain the normal 
structure or function in 
humans 
Not required to be pre-
approved 
Health claims must be 
consistent with recognized 
physiological effect and the 
degree to which the claimed 
effect is demonstrated. 
Evaluated before marketing 
Health claims regarding 
preventing Schedule A 
diseases are allowed 
provided that they are 
supported by sufficient 
evidence  
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Table 1.2 Milk thistle interaction kinetics in enzyme preparations. 
Enzyme Source 
Milk Thistle 
Preparation 
Enzyme Substrate Outcome Reference 
Pooled HLM 
Silybin A 
CYP2C9 (S)-Warfarin 
Ki, 10 µM (Brantley et al., 
2010)  Silybin B Ki, 4.8 µM 
E. coli expressed Silibinin 
CYP2C9 7-EFC
a
 KI 5 µM 
(Sridar et al., 
2004)  CYP3A4 
7-BFC
b
 KI 32 µM 
Testosterone KI 166 µM 
HLM  
(2 preparations) 
Silibinin 
CYP1A2 Caffeine IC50, >200, >200 µM 
(Beckmann-
Knopp et al., 
2000) 
CYP2A6 Coumarin IC50, >200, >200 µM 
CYP2C9 (S)-Warfarin IC50, 43, 45 µM 
CYP2C19 (S)-Mephenytoin IC50, >200, >200 µM 
CYP2D6 Dextromethorphan IC50, 173, >200 µM 
CYP2E1 Chlorozoxazone IC50, >200, >200 µM 
CYP3A4 
Denitronifedipine IC50, 29,46 µM 
Erythromycin IC50, >200, >200 µM 
HLM  
(2 preparations) 
Silibinin 
CYP2D6 Bufuralol Ki, nd, 8.2 µM 
(Zuber et al., 
2002)  
CYP2E1 ρ-Nitrophenol Ki, nd, 28.7 µM 
CYP3A4 Nifedipine Ki, 4.9, 9.0  µM 
Pooled HLM Silibinin 
CYP1A2 Ethoxyresorufin Ki, 165 µM 
(Jancova et al., 
2007)  
CYP2C9 Diclofenac Ki, 75 µM 
CYP3A4 Testosterone Ki, 21 µM 
Pooled HLM Silymarin
c
 
CYP2C19 (S)-Mephenytoin Ki,  2.2 µM 
(Doehmer et 
al., 2008)  
CYP2D6 Bufarolol Ki,  11.6 µM 
CYP3A4 Testosterone Ki,  12.0 µM 
Pooled HLM 
Milk Thistle 
Extract 
CYP2C8 Paclitaxel Ki, 8.35 µg/mL 
(Doehmer et 
al., 2011) 
CYP2C9 Diclofenac Ki, 9.42 µg/mL 
CYP2C19 Mephenytoin Ki, 33.0 µg/mL 
CYP2D6 Bufarolol Ki, 68.9 µg/mL 
CYP3A4 Testosterone Ki, 12.5 µg/mL 
Pooled (n=3) HLM 
Milk Thistle 
Extract
d
 
CYP1A2 Acetanilide 
<20% ↓ in activity  
at 10 µM 
(Etheridge et 
al., 2007)  
CYP2C8 Paclitaxel 
66% ↓ in activity  
at 10 µM 
CYP2C9 Tolbutamide 
No inhibition at 1 
µM
e
 
CYP2C19 (S)-Mephenytoin 
<30% ↓ in activity  
at 10 µM 
CYP2D6 Dextromethorphan 
<20% ↓ in activity  
at 10 µM 
CYP2E1 ρ-Nitrophenol 
<20% ↓ in activity  
at 10 µM 
CYP3A4 
Midazolam 
43% ↓ in activity  
at 10 µM 
Testosterone 
43% ↓ in activity  
at 10 µM 
Recombinant Silibinin 
UGT1A1 
7-HFC
f
 
IC50, 1.4 µM 
(Sridar et al., 
2004)  
UGT1A6 IC50, 28 µM 
UGT1A9 IC50, 20 µM 
UGT2B7 IC50, 92 µM 
UGT2B15 IC50, 75 µM 
Pooled HLM 
Milk Thistle 
Extract 
UGT1A1 Estradiol IC50, 18 µg/mL 
(Mohamed et 
al., 2010)  
Pooled HLM 
Milk Thistle 
Extract 
UGT1A4 Trifluoperazine Interference 
(Mohamed and 
Frye, 2011) 
UGT1A6 Seratonin IC50, 59.5 µg/mL 
UGT1A9 Mycophenolic acid IC50, 33.6 µg/mL 
HLM, human liver microsomes; nd, not determined 
a7-EFC, 7-ethoxy-4-(trifluoromethyl)coumarin 
b7-BFC, 7-benzyloxy-4-(trifluoromethyl)coumarin 
cConcentrations reported as silibinin equivalents 
d Standardized to silybin B (21.1% of extract) content  
eActivity not reported at 10 µM 
f7-HFC, 7-hydroxy-4-(trifluoromethyl)coumarin 
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Table 1.3 Milk thistle interaction kinetics in cell systems. 
Cell System 
Milk Thistle  
Preparation 
Enzyme or 
Transporter 
Substrate 
Incubation 
Conditions 
Outcome Reference 
Human 
Hepatocytes 
Silymarin 
CYP3A4 Testosterone 
48 hours  
at 100 µM 
50% ↓ in activity  (Venkataram
anan et al., 
2000)  
UGT1A6/9 4MU 65% ↓ in activity  
Human 
hepatocytes 
Silibinin 
CYP1A2 
NA 
72 hours  
at 100 µM 
No change in 
mRNA or 
protein 
expression 
(Kosina et al., 
2005)  
CYP3A4 
Human 
Hepatocytes 
Silymarin 
CYP2C9 Diclofenac 72 hours  
at 100 µM 
No induction 
(Doehmer et 
al., 2008)  CYP3A4 Testosterone 
Human 
Hepatocytes 
(3 donors per 
enzyme) 
Milk Thistle 
Extract 
CYP1A2 
7-
Ethoxyresorufin 
72 hours  
at 50 µg/mL 
1.1-8.5 fold 
induction  
(Doehmer et 
al., 2011)  
CYP2B6 
(S)-
Mephenytoin 
0.3-2.7 fold 
induction  
CYP2C9 Diclofenac 
0.7-1.6 fold 
induction  
CYP2E1 Chlorzoxazone 
2.0-3.0 fold 
induction  
CYP3A4 Testosterone 
0.4-1.3 fold 
induction  
Caco-2 cells Silibinin 
CYP3A4  
NA 
48 hours  
at 10 µM 
9% ↓ in protein (Budzinski et 
al., 2007)  P-gp 69% ↑ in protein 
Caco-2 cells Silymarin P-gp 
Digoxin 
1 hour  
at 150 µM 
23% ↑ in 
accumulation 
(Zhang and 
Morris, 
2003a)  Vinblastine 
80% ↑ in 
accumulation 
Caco-2 cells 
Silibinin 
CYP3A4 Cortisol 
30 minutes 
No inhibition 
(Patel et al., 
2004)  
P-gp Ritonavir 
No change in 
transport  MDR1 
transfected 
MDCK cells 
P-gp Ritonavir 
MDA435/LC
C6 cells 
Silymarin P-gp Daunomycin 
2 hours at  
50 µM 
4.5 fold ↑ in 
accumulation 
(Zhang and 
Morris, 
2003b)  
Panc-1 cells Silymarin MRP1 
Daunomycin 
2 hours at  
100 µM 
3.1 fold ↑ in 
accumulation (Nguyen et 
al., 2003)  
Vinblastine 
3.3 fold ↑ in 
accumulation 
BCRP-
overexpressi
ng 
membrane 
vesicles 
Milk Thistle 
Extract 
BCRP Methotrexate 
2 minutes at 
1,000 µg/mL 
45.4% ↓ in 
transport  
(Tamaki et 
al., 2010)  
MCF-7 
MX100 cells 
Silymarin BCRP Mitoxantrone 
15 min 
preincubation
, 30 min 
coincubation 
EC50, 33.7 µM 
(Zhang et al., 
2004)  
BCRP 
transfected 
MDCK cells 
Silymarin 
BCRP 
Rosuvastatin 
1 h 
incubation 
Ki, 97.9 uM 
(Deng et al., 
2008)  
OATP1B1 
transfected 
xenopus 
oocytes 
OATP1B1 
30 min 
incubation 
Ki, 0.93 uM 
HEK293-
OATP1B1 
Silymarin 
OATP1B1 
Estradiol-17-β-
glucuronide 3 min 
incubation 
IC50, 1.3 µM 
(Köck et al., 
2013) 
HEK293-
OATP1B3 
OATP1B3 IC50, 2.2 µM 
MDCKII-
OATP2B1 
OATP2B1 
Estrone-3-
sulfate 
IC50, 0.3 µM 
4MU, 4-methylumbelliferone; NA, not applicable  
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Table 1.4 Milk thistle interaction kinetics in pre-clinical animal models. 
Milk Thistle Preparation 
Animal 
Species (n) 
Test 
Substrate 
Administratio
n Regimen 
Enzyme
a
 or 
Transporter
 Outcome Reference 
Silibinin 0.5 mg/kg PO
b
 
Rats (6/arm) 
Tamoxifen 
10 mg/kg PO 
CYP3A4 
CYP2D6 
P-gp 
1.2 fold ↑ in Cmax 
1.2 fold ↑ in AUCinf 
(Kim et al., 
2010) 
Silibinin 2.5 mg/kg PO 
1.5 fold ↑ in Cmax 
1.4 fold ↑ in AUCinf 
Silibinin 10 mg/kg PO 
1.8 fold ↑ in Cmax 
1.7 fold ↑ in AUCinf 
Silibinin 175 mg/kg 
7 days prior to test 
substrate 
Male Sprague-
Dawley Rats 
(6/arm) 
Trazodone 
5 mg/kg IV
c
 
CYP3A4 
12% ↓ in Cmax 
No change in AUC 
(Chang et 
al., 2009) 
Silibinin 350 mg/kg 
7 days prior to test 
substrate 
30% ↓ in Cmax 
8% ↓ in AUC 
Silymarin 500 mg/kg 
7 days prior to test 
substrate 
No change in Cmax 
20% ↓ in AUC 
Silymarin 1,000 mg/kg 
7 days prior to test 
substrate 
No change in Cmax 
43% ↓ in AUC 
Silymarin 1,000 mg/kg 
4 hours prior to test 
substrate 
238% ↑ in Cmax 
3% ↑ in AUC 
Silymarin 40 mg/kg PO 
coadministered with test 
substrate 
Rats 
Resperidone 
6 mg/kg PO 
P-gp 
1.3 fold ↑ in Cmax 
No change in AUCinf 
(Lee et al., 
2013) Silymarin 40 mg/kg PO 
5 days prior to test 
substrate 
2.4 fold ↑ in Cmax 
1.7 fold ↑ in AUCinf 
Silibinin 30 mg/kg IV 
Rats (6/arm) 
Pyrazinamide 
50 mg/kg IV 
Xanthine 
oxidase 
21% ↑ in Cmax 
5% ↑ in AUC 
(Wu and 
Tsai, 
2007) 
Pyrazinoic acid 
30 mg/kg IV 
320% ↑ in Cmax 
420% ↑ in AUC 
Silibinin 100 mg/kg PO 
for 4 days 
Pyrazinamide 
50 mg/kg IV 
22% ↑ in Cmax 
6% ↓ in AUC 
Pyrazinoic acid 
30 mg/kg IV 
260% ↑ in Cmax 
350% ↑ in AUC 
aHuman ortholog responsible for metabolism/transport of test substrate 
bOrally administered 
cIntravenously administered 
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Table 1.5 Clinical evaluation of milk thistle drug interaction liability 
Milk Thistle 
Preparation 
Administration 
Regimen 
Subjects (n) 
Probe 
Substrate 
Administration 
Regimen 
Enzyme or 
Transporter 
Clinical Outcome Reference 
Milk Thistle 
175 mg BID  
for 4 weeks 
12 healthy 
volunteers 
(6 women) 
Caffeine  
100 mg 
CYP1A2 
4.8% ↓ in Phenotypic 
Ratio 
(Gurley et 
al., 2004) 
Debrisoquine  
5 mg  
CYP2D6 
1.0% ↓ in Phenotypic 
Ratio 
Clorzoxazone  
250 mg  
CYP2E1 
1.1% ↑ in Phenotypic 
Ratio 
Midazolam  
8 mg  
CYP3A4 
7.8% ↓ in Phenotypic 
Ratio 
Milk Thistle 
175 mg TID  
for 2 weeks 
 
6 healthy 
Chinese men 
(CYP2C9*1/*1) Losartan  
50 mg 
CYP2C9 
90% ↑ in Cmax 
110% ↑ in AUC0-inf 
(Han et al., 
2009b) 6 healthy 
Chinese men 
(CYP2C9*1/*3) 
41% ↑ in Cmax 
1.0% ↑ in AUC0-inf 
Milk Thistle 
300 mg TID  
for 2 weeks 
16 healthy 
volunteers (8 
women) 
Debrisoquine  
5 mg 
CYP2D6 
3.2% ↓ in urinary 
recovery ratio 
(Gurley et 
al., 2008) 
Milk Thistle 
200 mg TID  
for 4 days 6 cancer patients 
(4 women) 
Irinotecan 125 
mg/m2 90 min IV 
infusion 
CYP3A4 
and 
UGT1A1 
7.7% ↑ in Cmax 
16% ↑ in AUC (van Erp et 
al., 2005) 
200 mg TID  
for 12 days 
3.2% ↑ in Cmax 
14% ↑ in AUC 
Milk Thistle 
175 TID  
for 3 weeks 
10 healthy 
volunteers 
(4 women) 
Indinavir 800 mg 
4 doses 8 hours 
apart 
CYP3A4 
9.2% ↓ in Cmax 
8.8% ↓ in AUC0-8 
(Piscitelli et 
al., 2002) 
Milk Thistle 
160 mg TID  
for 2 weeks 
10 healthy 
volunteers 
(3 women) 
Indinavir 800 mg 
4 doses 8 hours 
apart 
CYP3A4 
11% ↓ in Cmax 
6.3% ↓ in AUC0-8 
(DiCenzo 
et al., 
2003) 
Milk Thistle 
450 mg TID  
for 30 days 
16 healthy male 
volunteers 
800 mg indinavir 
3 doses 8 hours 
apart 
CYP3A4 
4.9% ↓ in Cmax 
4.4% ↓ in AUC0-8 
(Mills et al., 
2005) 
Milk Thistle 
150 mg TID  
for 2 weeks 
15 male HIV 
patients (4 co-
infected with 
HCV) 
Darunavir  
600 mg  
CYP3A4 
17% ↓ in Cmax 
14% ↓ in AUC0-12 (Molto et 
al., 2012) Ritonavir  
100 mg  
10% ↓ in Cmax 
11% ↓ in AUC0-12 
Milk thistle extract 
300 mg TID  
for 14 days 
19 healthy 
volunteers 
(9 women) 
Midazolam  
8 mg 
CYP3A4 
6.5% ↑ in Cmax 
2.8% ↑ in AUC 
(Gurley et 
al., 2006a) 
Milk Thistle 
280 mg 10 and 1.5 
hours before 
nifedipine 
16 healthy male 
volunteers 
Nifedipine 
10 mg 
CYP3A4 
30% ↓ in Cmax 
13% ↑ in AUC0-inf 
(Fuhr et al., 
2007) 
Silymarin 
140 mg TID  
for 14 days 
12 healthy male 
volunteers 
Ranitidine  
150 mg  
CYP3A4 
and P-gp 
7.6% ↑ in Cmax 
4.2% ↓ in AUC0-12 
(Rao et al., 
2007) 
Silymarin 
140 mg TID  
for 3 days before 
and 2 days after 
rosuvastatin 
8 Healthy Korean 
men 
Rosuvastatin  
10 mg  
1 hour after AM 
silymarin 
OATP1B1 & 
BCRP 
7.5% ↓ in Cmax 
6.5% ↓ in AUC 
(Deng et 
al., 2008) 
Milk Thistle 
175 mg TID  
for 2 weeks 
6 healthy 
Chinese men 
MDR1 3435CC 
Talinolol  
100 mg  
P-gp 
43% ↑ in Cmax 
22% ↑ in AUC0-inf 
(Han et al., 
2009a) 
6 healthy 
Chinese men 
MDR1 3435CT 
40% ↑ in Cmax 
37% ↑ in AUC0-inf 
6 healthy 
Chinese men 
MDR1 3435TT 
1% ↑ in Cmax 
21% ↑ in AUC0-inf 
Milk thistle 
300 mg TID  
for 14 days 
16 healthy 
volunteers 
(8 women) 
Digoxin  
0.4 mg  
P-gp 
13% ↓ in Cmax 
9.4% ↓ in AUC0-24 
(Gurley et 
al., 2006b) 
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Figure 1.2. Chemical structures of milk thistle constituents 
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Chapter 2 
 
Two Flavonolignans from Milk Thistle (Silybum marianum) Inhibit CYP2C9-Mediated 
Warfarin Metabolism at Clinically Achievable Concentrations1,2 
 
Overview 
Milk thistle (Silybum marianum) is a popular herbal product used for 
hepatoprotection and chemoprevention.  Two commercially available formulations are 
the crude extract, silymarin, and the semi-purified product, silibinin.  Silymarin consists of 
at least seven flavonolignans, of which the most prevalent are the diastereoisomers 
silybin A and silybin B; silibinin consists only of silybin A and silybin B.  Based on a 
recent clinical study showing an interaction between a silymarin product and the 
CYP2C9 substrate losartan, the CYP2C9 inhibition properties of silybin A and silybin B, 
and corresponding regioisomers, isosilybin A and isosilybin B, were evaluated using 
human liver microsomes (HLM), recombinant CYP2C9 (rCYP2C9) enzymes, and the 
clinically relevant probe, (S)-warfarin.  Silybin B was the most potent inhibitor in HLM, 
followed by silybin A, isosilybin B, and isosilybin A (IC50 of 8.2, 18, 74, and >100 µM, 
respectively).  Next, silybin A and silybin B were selected for further characterization.  As 
with HLM, silybin B was more potent than silybin A towards rCYP2C9*1 (6.7 vs. 12 μM), 
                                                          
1 Brantley SJ, Oberlies NH, Kroll DJ and Paine MF (2010) Two flavonolignans from milk 
thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically 
achievable concentrations. J Pharmacol Exp Ther 332:1081-1087. 
 
2 Reprinted with permission of the American Society for Pharmacology and Experimental 
Therapeutics. All rights reserved. 
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rCYP2C9*2 (9.3 vs. 19 μM), and rCYP2C9*3 (2.4 vs. 9.3 µM).  Using a matrix of 5 
substrate (1-15 µM) and 6 inhibitor (1-80 µM) concentrations and HLM, both 
diastereoisomers inhibited (S)-warfarin 7-hydroxylation in a manner described best by a 
mixed-type inhibition model (Ki of 4.8 and 10 μM for silybin B and silybin A, respectively).  
These observations, combined with the high systemic silibinin concentrations (>5-75 μM) 
achieved in a phase I study involving prostate cancer patients, prompt clinical evaluation 
of a potential warfarin-milk thistle interaction.    
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Introduction 
Milk thistle [Silybum marianum (L.) Gaertn] is a resilient and sometimes noxious 
plant that has been valued for its medicinal qualities for over 2000 years (Kroll et al., 
2007; Post-White et al., 2007).  In modern herbal compendia, milk thistle is used to self-
treat hepatic disorders, including hepatitis C and cirrhosis, and as a hepatoprotectant, 
particularly for mushroom poisoning.  Milk thistle is available mainly as an extract 
prepared from the seeds of the plant.  The two most common commercial preparations 
are termed silymarin and silibinin.  Silymarin, a crude extract, is a complex mixture of at 
least seven flavonolignans and one flavonoid (taxifolin) (Kroll et al., 2007).  The most 
abundant flavonolignans are the diastereoisomers silybin A and silybin B (Fig. 2.1).  The 
diastereoisomers isosilybin A and isosilybin B (Fig. 2.1) also are present and are 
regioisomers of silybin A and silybin B.  The remaining three flavonolignans are 
silychristin, isosilychristin, and silydianin, all of which are constitutional isomers of the 
aforementioned compounds.  Silibinin is a semi-purified extract, representing 
approximately a 1:1 mixture of silybin A and silybin B.  Because silymarin and silibinin 
are mixtures of compounds derived from a natural source, batch-to-batch variation in 
bioactive ingredient composition occurs, which can confound the interpretation of study 
results (Kroll et al., 2007).  Fortuitously, methods have been developed to isolate and 
purify gram quantities of each flavonolignan from milk thistle extract, permitting 
delineation of the disposition and action of single constituents (Kim et al., 2001; Graf et 
al., 2007). 
Milk thistle has garnered attention since the 1990s for its chemopreventive 
properties, particularly for prostate cancer (Agarwal et al., 2006; Gazak et al., 2007; Kroll 
et al., 2007).  With the advent of single components from silymarin, the antiproliferative 
effects of each flavonolignan, as well silymarin and silibinin, were compared using 
human prostate cancer cell lines; at concentrations ranging from 15-90 μM, isosilybin B 
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was consistently the most potent of all the individual components and mixtures 
examined (Davis-Searles et al., 2005).  In rodent models of prostate cancer, dietary 
feeding of silymarin and silibinin has been shown, respectively, to decrease the 
incidence of 3,2’-dimethyl-4-aminobiphenyl-induced prostatic adenocarcinoma (Kohno et 
al., 2005) and to inhibit prostate tumor growth (Ramasamy and Agarwal, 2008; Singh et 
al., 2008).  The latter studies set the target systemic concentration of silibinin at 10-15 
μM. 
Clinical studies have indicated that both silymarin and silibinin have poor oral 
bioavailability due to extensive first-pass conjugation via UDP-glucuronosyl transferases 
and sulfotransferases (Flaig et al., 2007; Schrieber et al., 2008; Wen et al., 2008).  As 
such, at typical “doses”, systemic concentrations of unconjugated flavonolignans >1 μM 
are rarely achieved.  The first study to demonstrate systemic concentrations of 
unconjugated silibinin in the purported therapeutic range was a phase I dose-escalation 
study involving prostate cancer patients (Flaig et al., 2007).  These patients were 
administered 2.5 to 20 g/day of a silibinin-phosphatidylcholine complex (Siliphos®), 
which has improved absorption characteristics, and presumably an improved 
bioavailability, compared to non-complexed silibinin (Flaig et al., 2007).  Average peak 
plasma concentrations of unconjugated silibinin ranged from 5-75 μM.  Moreover, these 
high doses were well-tolerated, and several patients experienced prolonged stable 
disease, prompting a phase II study that is currently underway. 
Herbal products often are taken concomitantly with medications, which could 
potentially lead to dangerous interactions (Hu et al., 2005; Wu et al., 2009).  Clinical 
studies involving milk thistle extracts to date have shown minimal to no drug interaction 
liability, at least with drugs that are considered probe substrates for CYP1A2, CYP2D6, 
CYP2E1, CYP3A, and the efflux transporter P-glycoprotein (Gurley et al., 2004; Gurley 
et al., 2006a; Gurley et al., 2006b; Gurley et al., 2008).  A caveat to these studies is that 
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a low total daily “dose” (<1 g) of extract (silymarin) was given, which is much less than 
that postulated to have clinical benefit, at least for prostate cancer.  However, a recent 
healthy volunteer study demonstrated an interaction between the antihypertensive agent 
and CYP2C9/CYP3A substrate losartan and silymarin, the latter of which was given as a 
low total daily dose (420 mg) (Han et al., 2009).  Relative to placebo, in CYP2C9*1 
carriers, silymarin decreased the AUC ratio of the CYP2C9-mediated active metabolite, 
E-3174, to that of losartan, by ~50% (p<0.05), suggesting inhibition of hepatic CYP2C9 
by one or more components of silymarin.  These observations, coupled with the high 
systemic concentrations observed in the dose-escalation study, prompted a systematic 
evaluation of the inhibitory effects of individual components from silymarin on the 
CYP2C9-mediated metabolism of another clinically relevant substrate, (S)-warfarin, the 
more pharmacologically active enantiomer of the widely prescribed oral anticoagulant 
warfarin.  Specifically, the inhibitory potency of four key flavonolignans (silybin A, silybin 
B, isosilybin A, isosilybin B) toward (S)-warfarin 7-hydroxylation were compared using 
human liver microsomes and recombinant CYP2C9 enzymes.  To the authors’ 
knowledge, this work represents the first evaluation of the drug interaction liability of 
single, purified constituents from milk thistle. 
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Materials and Methods 
Chemicals and reagents.  Human liver microsomes (HLM; pooled from 50 
donors, mixed gender) were purchased from Xenotech, LLC (Lenexa, KS).  Baculovirus-
insect cell-expressed CYP2C9*1, CYP2C9*2, CYP2C9*3 (supplemented with cDNA-
expressed reductase but not cytochrome b5), tienilic acid, and 7-hydroxywarfarin were 
purchased from BD Biosciences (San Jose, CA).  (S)-warfarin, chlorowarfarin, NADPH, 
and HPLC grade water, methanol, ammonium acetate, and 1-propanol were purchased 
from Sigma-Aldrich (St. Louis, MO).  Silybin A, silybin B, isosilybin A, and isosilybin B 
were isolated from milk thistle extract as described previously (Graf et al., 2007); all 
flavonolignans were >97% pure as determined by HPLC. 
 Evaluation of silymarin flavonolignans as inhibitors of CYP2C9 activity.  
The inhibitory effects of each flavonolignan on (S)-warfarin 7-hydroxylation were 
evaluated using pooled HLMs and recombinant CYP2C9 (rCYP2C9).  (S)-Warfarin and 
sulfaphenazole were dissolved in methanol to yield a working concentration of 10 mM 
and 1 mM, respectively.  Each flavonolignan was dissolved in methanol to yield a 
working concentration of 50 mM.  NADPH was dissolved fresh in potassium phosphate 
buffer (0.1 M, pH 7.4) to yield a working concentration of 4 mM.  Incubation mixtures 
were prepared in 96-well plates.  Under all experimental conditions, the amount of 7-
hydroxywarfarin formed was linear with respect to incubation time and mass/amount of 
microsomal protein or rCYP2C9 (data not shown).  Initial testing.  Incubation mixtures 
consisted of HLMs (0.1 mg/mL microsomal protein), (S)-warfarin (4 μM), flavonolignan 
(1, 10, and 100 μM), and potassium phosphate buffer (100 mM, pH 7.4).  As a positive 
control for CYP2C9 inhibition, incubation mixtures contained sulfaphenazole (1 μM) in 
place of flavonolignan.  Control incubation mixtures contained 0.75% methanol (v/v) in 
place of flavonolignan/sulfaphenazole.  The plates were placed on a dry heat block, and 
the mixtures were equilibrated for 5 minutes at 37°C before initiating the reactions with 
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NADPH (1 mM final concentration) to yield a final volume of 200 μL.  After 30 minutes, 
the reactions were quenched with 400 μL of cold methanol containing 3.33 nM 
chlorowarfarin as the internal standard.  After centrifugation (1350 x g for 10 minutes at 
4C), the supernatant (8 μL) was analyzed for 7-hydroxywarfarin by LC-MS/MS 
(described below).  Ki determination for silybin A and silybin B using HLMs.  Incubation 
mixtures were prepared in a similar manner as described above using a 5 x 6 matrix of 
substrate (1-15 μM) and flavonolignan (1-80 μM) concentrations.  The reaction mixtures 
were processed further and analyzed for 7-hydroxywarfarin as described above.  IC50 
determination for silybin A and silybin B using rCYP2C9 enzymes.  Incubation mixtures 
consisting of rCYP2C9 (12.5 pmol/mL), (S)-warfarin (4 μM), flavonolignan (0.5-100 μM), 
and potassium phosphate buffer were equilibrated for 5 minutes at 37°C before initiating 
the reactions with NADPH.  After 30 (rCYP2C9*1, rCYP2C9*2) or 60 (rCYP2C9*3) 
minutes, the reactions were quenched and processed as described above.  Testing of 
silybin A and silybin B as mechanism-based inhibitors of CYP2C9 using HLMs.  IC50 shift 
experiments (Obach et al., 2007) were utilized to determine whether silybin A and silybin 
B are mechanism-based inhibitors of hepatic CYP2C9 activity.  Primary incubation 
mixtures consisting of HLMs (1 mg/mL), flavonolignan (0.1-1000 μM), and potassium 
phosphate buffer were equilibrated for 5 minutes at 37°C before initiating the reactions 
with NADPH.  Control primary reaction mixtures were identical except that NADPH was 
absent.  As a positive control for mechanism based inhibition, incubation mixtures 
contained tienilic acid (1.0-500 μM) in place of flavonolignan. After 30 minutes, an aliquot 
(20 μL) was removed and diluted 10-fold into a secondary incubation mixture containing 
(S)-warfarin (4 μM) and NADPH (1 mM).  After an additional 30 minutes, the secondary 
reactions were quenched and processed as described above. 
Analysis of microsomal incubations for 7-hydroxywarfarin.  7-
Hydroxywarfarin was quantified by LC-MS/MS using a Shimadzu solvent delivery system 
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(Columbia, MD) and a Leap HTC Pal thermostated autosampler (Carrboro, NC) 
connected to an Applied Biosystems (Foster City, CA) API 4000 triple quadruple mass 
spectrometer equipped with a TurboSpray® ion source.  Tuning, operation, integration, 
and data analysis were carried out in negative mode using multiple reaction monitoring 
(Analyst® software v.1.4.1, Applied Biosystems).  Analytes (7-hydroxywarfarin, 
chlorowarfarin), as well as other metabolites, were separated using a Gemini® C18 
column (30 x 2.0 mm, 5 µm particle size; Phenomenex, Torrance, CA) and a solvent flow 
rate of 0.75 mL/min.  Initial gradient conditions were 100% 10 mM ammonium acetate, 
which were held for 0.7 min while the eluent was directed to waste.  From 0.7 min to 4.5 
min, the mobile phase composition increased linearly to 60% methanol, and the eluent 
was directed to the mass spectrometer.  At 5.0 min, the eluent was directed again to 
waste, and the column was flushed with 80% methanol for 0.4 min.  From 6.0 to 6.5 min, 
the system was equilibrated with 100% 10 mM ammonium acetate.  Total run time, 
including equilibration, was 6.5 minutes per injection.  Duplicate ten-point calibration 
curves for 7-hydroxywarfarin (0.2 to 100 nM) were constructed using the peak area ratio 
of 7-hydroxywarfarin (323.06→176.8; retention time, 3.34 min) to chlorowarfarin 
(341.2→160.9; retention time, 4.24 min).  Interday accuracy and precision ranged from 
99-110% and from 9.0-12%, respectively, for all quality controls (0.23, 1.5, 15 pmol).   
Data analysis.  Apparent IC50 determination.  Initial estimates of apparent IC50 
values were derived from linear regression of the velocity vs. natural logarithm of 
flavonolignan concentration data.  Apparent IC50 values were determined by fitting the 
following equation with untransformed data using WinNonlin (v5.0.1, Pharsight, 
Mountain View, CA): 
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where I denotes the concentration of inhibitor, and v0 and v denote the velocity of 7-
hydroxywarfarin formation in the absence and presence of flavonolignan, respectively.  
Apparent Ki determination.  Initial estimates of apparent Km and Vmax were derived from 
Eadie-Hofstee plots of the velocity vs. velocity/[substrate] data in the absence of 
flavonolignan.  Initial estimates of apparent Ki values were derived from Dixon plots of 
velocity-1 vs. flavonolignan concentration data.  Kinetic parameters (Km, Vmax, Ki) were 
obtained by fitting the following inhibition equations for a unienzyme system with 
untransformed data:    
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where S denotes the concentration of (S)-warfarin, I denotes the concentration of 
inhibitor, and α (Eq. 4) denotes a parameter to describe the affinity change of the 
enzyme-substrate and enzyme-inhibitor complexes (Geng, 2003).  When α =1, Eq. 4 
simplifies to the pure non-competitive inhibition model (Eq. 3); when α is very large 
(approaches infinity), Eq. 4 simplifies to the pure competitive inhibition model (Eq. 2).  
The best-fit equation was assessed from visual inspection of the observed vs. predicted 
data, randomness of the residuals, Akaike information criteria, and standard errors of the 
parameter estimates.  Apparent intrinsic clearance (Clint) was calculated as the ratio of 
Vmax to Km.   
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Statistical analysis.  All statistical analyses were carried out using SigmaStat 
(v3.5, Systat Software, Inc., San Jose, CA).  Data are presented as means  SDs of 
triplicate determinations, unless indicated otherwise.  Concentration-dependent inhibition 
of each flavonolignan in HLMs was evaluated by 1-way ANOVA; post-hoc comparisons 
were made using Tukey’s test when an overall difference resulted (p<0.05).  Enzyme 
kinetic parameters are presented as the estimates ± SEs.  Statistical differences 
between the calculated IC50 for silybin A and silybin B within an enzyme source was 
evaluated by a Student’s t-test of 2 independent samples; a p-value <0.05 was 
considered significant. Statistical differences between the calculated IC50 for a given 
inhibitor among enzyme sources was evaluated by 1-way ANOVA; post-hoc 
comparisons were made using Tukey’s test when an overall difference resulted (p<0.05).   
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Results 
Selected flavonolignans differentially inhibit CYP2C9-mediated warfarin 
metabolism.  Each flavonolignan inhibited the 7-hydroxylation of (S)-warfarin in a 
concentration-dependent manner, with the diastereoisomer pair, silybin A and silybin B, 
showing greater potency than their regioisomer counterparts, isosilybin A and isosilybin 
B (Fig. 2.2).  Within each diastereoisomer pair, the B forms were slightly more potent 
than the A forms.  As reflected by the IC50 values, silybin B was the most potent of the 
flavonolignans tested, followed by silybin A, isosilybin B, and isosilybin A (Table 2.1).  
Isosilybin A and isosilybin B were not evaluated further due the relative lack of inhibitory 
potency.   
 Silybin B is a more potent inhibitor of CYP2C9-mediated warfarin 
metabolism than silybin A.  The apparent Ki for silybin A and silybin B towards (S)-
warfarin 7-hydroxylation was determined using a 5 x 6 matrix of substrate-inhibitor 
concentrations and HLMs (Fig. 2.3).  The simple linear mixed-type inhibition model (Eq. 
3) best described the data for both silybin A and silybin B.  In the absence of inhibitor, 7-
hydroxywarfarin formation was consistent with classic Michaelis-Menten unienzyme 
kinetics, as evidenced by linear Eadie-Hofstee plots (not shown).  The Km and Vmax of 7-
hydroxywarfarin formation were, respectively, 4.0 ± 0.5 μM and 7.7 ± 0.5 pmol/min/mg 
protein (silybin A) or 3.4 ± 0.4 μM and 9.1 ± 0.6 pmol/min/mg protein (silybin B).   Clint 
values were 1.9 and 2.7 μL/min/mg, respectively.  The Ki for silybin A was twice that for 
silybin B (Fig. 2.3).  The α value for silybin A and silybin B was 5 and 8, respectively.  As 
observed with HLMs, silybin B was more potent than silybin A with all recombinant 
enzyme variants (Fig. 2.4).  At the lowest flavonolignan concentration tested, the velocity 
for CYP2C9*1 was approximately twice that of CYP2C9*2, which was approximately 
twice that of CYP2C9*3.  For a given inhibitor, the calculated IC50 value for CYP2C9*3 
was significantly lower than that for HLM, CYP2C9*1, and CYP2C9*2 (Table 2.1).    
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 Silybin A and silybin B appear not to be mechanism-based inhibitors of (S)-
warfarin 7-hydroxylation.  IC50 shift experiments with HLMs were carried out to 
determine whether silybin A and silybin B are mechanism-based inhibitors of hepatic 
CYP2C9. When NADPH was absent from the primary incubation mixture, the calculated 
IC50 values for each flavonolignan agreed with those from initial experiments (Table 2.1).  
When NADPH was present in the primary reaction mixture, IC50 values remained 
unchanged (Fig. 2.5).  The calculated IC50 values for the positive control, tienilic acid, 
shifted from 12 ± 0.9 μM in the absence of NADPH to 1.7 ± 0.1 μM in the presence of 
NADPH. 
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Discussion 
Warfarin is a widely prescribed oral anticoagulant used to treat thromboembolic 
disorders (Rettie and Tai, 2006).  Despite over 50 years of clinical experience, optimal 
warfarin therapy remains challenging due to a narrow therapeutic window and large 
inter-patient differences in anticoagulant response.  As such, the daily therapeutic 
warfarin dose varies by more than an order of magnitude in a given population (Rettie 
and Tai, 2006).  The clinically available formulation of warfarin is a racemic mixture, with 
the S-enantiomer having an estimated five-fold greater pharmacologic potency than the 
R-enantiomer (Jonas and McLeod, 2009).  (S)-Warfarin is eliminated from the body 
almost exclusively via hepatic metabolism by CYP2C9, with 7-hydroxylation representing 
the major metabolic pathway (Jonas and McLeod, 2009).  Accordingly, any process that 
significantly impairs CYP2C9 activity would be expected to decrease the clearance of 
(S)-warfarin and increase anticoagulant response.  Indeed, a number of clinically used 
CYP2C9 inhibitors, e.g., fluconazole, amiodarone, and trimethoprim/sulfamethoxazole, 
have been associated with serious bleeding events in patients receiving warfarin (Thi et 
al., 2009).  
 Whereas specific drugs have been identified as CYP2C9 inhibitors, such is not 
the case for herbal products, which continue to increase in popularity as complementary 
and alternative medicines for health maintenance, disease prevention, and even disease 
treatment (Ulbricht et al., 2008).  The fact that herbal products are derived from natural 
sources has led to the widespread notion that they are safe.  As such, these products 
often are taken with conventional medications, raising the potential for dangerous drug-
herb interactions.  Moreover, unlike most drug products, herbal products typically contain 
multiple bioactive ingredients that vary in composition between batches and 
manufacturers, precluding between-study comparisons, as well as accurate predictions 
of drug interaction liability (Paine and Oberlies, 2007).  A recent dose-escalation study 
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involving prostate cancer patients showed that oral gram doses of a crude/semi-purified 
extract of milk thistle, silibinin (2.5-20 g/day), were well-tolerated with minimal side 
effects; based on these encouraging results, a phase II study is underway (Flaig et al., 
2007; Kroll et al., 2007; Post-White et al., 2007).  Taken together, the goal of the current 
work was to characterize, systematically, the CYP2C9 inhibition properties of single 
constituents from milk thistle.  Based on previous studies that compared the 
antiproliferative effects of individual flavonolignans in prostate cancer cell lines, as well 
as to discern whether changes in stereo- and regiochemistry alter metabolic inhibition, 
four key flavonolignans (silybin A, silybin B, isosilybin A, isosilybin B) were selected for 
evaluation. 
Similar to the differential effects of individual flavonolignans observed in prostate 
cancer cell models (Davis-Searles et al., 2005), individual flavonolignans differentially 
inhibited the 7-hydroxylation of (S)-warfarin.  Whereas isosilybin A and isosilybin B were 
the most potent antiproliferative compounds, silybin A and silybin B were the most potent 
CYP2C9 inhibitors.  Based on the greater than 4-fold difference in IC50 values between 
silybin A/silybin B and isosilybin A/isosilybin B (<20 μM vs. >70 μM), the latter two 
flavonolignans were not evaluated further.  To determine the mode of CYP2C9 inhibition 
by silybin A and silybin B, reversible inhibition design experiments were undertaken that 
involved a range of substrate and flavonolignan concentrations.  The mixed-type model 
best described the data for compounds, producing Ki values of 4.8 and 10 µM, 
respectively.  The lack of mechanism-based inhibition, as evidenced from the IC50 shift 
experiments, is inconsistent with results obtained by Sridar et al. (2004), who reported a 
KI of 5 µM and a kinact of 0.14 min
-1.  These investigators used the semi-purified mixture, 
silibinin (termed silybin), a reconstituted enzyme system, and a fluorescent probe 
substrate, any or all of which could account for this between-laboratory discrepancy. 
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Xenobiotics, including drugs, herbal products, and dietary substances, are 
considered to have a high drug interaction liability when the ratio of in vivo inhibitor 
concentration to Ki is greater than unity (Bachmann and Lewis, 2005).  The average 
plasma, and presumably total (i.e., bound + unbound) concentrations of unconjugated 
silybin A/silybin B achieved in the prostate cancer patient dose-escalation study (Flaig et 
al., 2007) were at least five-fold greater than the apparent Ki values measured in the 
current work.  It should be noted that the systemic concentrations reported for these 
patients represented the sum of silybin A and silybin B.  Although dosed as a ~1:1 
mixture (i.e., silibinin), systemic concentrations cannot be considered 1:1 due to 
differential clearance (Kroll et al., 2007; Wen et al., 2008).  Despite this limitation, the low 
Ki values for both compounds compared to the high concentration of the mixture in 
plasma would necessitate caution when milk thistle products are taken with warfarin.  
The potential inter-product variation in milk thistle constituents in commercial products, 
along with the recent clinical study involving losartan and a silymarin product further 
support this contention. 
Two common single nucleotide polymorphisms in the coding region of the 
CYP2C9 gene, CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu), are known to 
influence warfarin anticoagulant response.  Both of the corresponding proteins have 
lower catalytic activity (approximately 50% and less than 10%, respectively) compared to 
the protein encoded by the reference allele, CYP2C9*1, and carriers of these variants 
often require a lower daily dose of warfarin (Jonas and McLeod, 2009).  CYP2C9*2 and 
CYP2C9*3 carriers also may require a longer period of time to become stabilized on 
warfarin therapy (Rettie and Tai, 2006).  Consistent with previous reports, in the absence 
of inhibitor, the velocity of 7-hydroxywarfarin formation with rCYP2C9*2 and rCYP2C9*3 
were roughly 50% and 25%, respectively, than that of rCYP2C9*1 (8.0, 3.6, and 15 
pmol/min/nmol, respectively).  Among the different recombinant enzyme preparations, 
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CYP2C9*3 was significantly more sensitive to inhibition by both silybin A and silybin B.  
These observations, coupled with the increased time to stabilize warfarin therapy and 
the increased bleeding risk that is associated with this variant, may suggest that co-
administration of warfarin and silymarin could further complicate therapy in CYP2C9*3 
carriers.  Despite the increased sensitivity of rCYP2C9*3, the relatively potent inhibition 
potential of these compounds toward rCYP2C9*1 and rCYP2C9*2 would not exclude 
CYP2C9*1 and CYP2C9*2 carriers from being at risk for a potential warfarin-milk thistle 
interaction. 
In summary, unlike drug products, dietary/natural products are not consistently 
regulated, and accordingly, are not required to undergo strict pre-clinical or clinical 
testing prior to marketing.  Patients often take these products with their medications, 
sometimes unbeknownst to their physicians and/or pharmacists, which can lead to 
potentially dangerous adverse events.  The current observations, combined with the 
reported interaction between silymarin and losartan (Han et al., 2009) and the inter-
product variation in milk thistle composition, prompts a clinical study with a standardized 
milk thistle product and warfarin.  Finally, the current work provides impetus to revisit 
P450-mediated drug-milk thistle interactions using purified single constituents. 
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Legends to Figures 
Fig. 2.1.  Structures of the four selected flavonolignans from milk thistle. 
Fig. 2.2.  Inhibitory effects of selected flavonolignans on (S)-warfarin 7-hydroxylation 
activity in human liver microsomes.  Human liver microsomes (0.1 mg/ml) were 
incubated with (S)-warfarin (4 μM) and flavonolignan (1, 10, or 100 μM; hatched, solid, 
and checkered bars, respectively) for 30 minutes.  Reactions were initiated by the 
addition of NADPH (1 mM).  (S)-Warfarin 7-hydroxylation activity in the presence of 
vehicle control (0.75% methanol, v/v) was 5.8  0.1 pmol/min/mg microsomal protein.  
Bars and error bars denote means and standard deviations, respectively, of triplicate 
incubations.  *p < 0.05 vs. flavonolignan at 10 μM; #p < 0.05 vs. flavonolignan at 1 μM (2-
way ANOVA, followed by Tukey’s test). 
Fig. 2.3.  Dixon plots showing the inhibition of (S)-warfarin 7-hydroxylation by silybin A 
(A) and silybin B (B) in human liver microsomes (HLMs).  HLMs (0.1 mg/ml) were 
incubated with (S)-warfarin (1-15 μM) and flavonolignan (1-80 μM silybin A or 1-50 μM 
silybin B) for 30 minutes.  Reactions were initiated by the addition of NADPH (1 mM).  
Symbols denote means of duplicate incubations.  Solid lines denote regression lines 
through values generated from a simple mixed-type inhibition model using WinNonlin 
(v5.0.1). 
Fig. 2.4.  Inhibitory effects of silybin A and silybin B on (S)-warfarin 7-hydroxylation 
activity in recombinant CYP2C9 enzymes.  Recombinant enzymes (12.5 pmol/ml) were 
incubated with (S)-warfarin (4 μM) and a range of concentrations (1-100 μM) of silybin A 
(boxes) or silybin B (triangles) for 30 (CYP2C9*1, CYP2C9*2) or 60 (CYP2C9*3) 
minutes.  Reactions were initiated by the addition of NADPH (1 mM).  (S)-Warfarin 7-
hydroxylation activity in the presence of vehicle control (0.75% methanol, v/v) was, 
respectively, 15  1.3, 8.0  0.4, and 3.6  0.3 pmol/min/nmol recombinant enzyme.  
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Symbols and error bars denote means and standard deviations, respectively, of triplicate 
incubations.  Solid (silybin A) and dashed (silybin B) curves denote nonlinear least-
squares regression of observed values using WinNonlin (v5.0.1).   
Fig. 2.5.  IC50 shift plot for silybin A and silybin B.  Human liver microsomes (0.1 mg/ml) 
were incubated first with silybin A (boxes) or silybin B (triangles) (0.1-1000 μM) (A) and 
tienilic acid (circles) (1-500 μM) (B) in the presence (closed symbols) or absence (open 
symbols) of NADPH (1 mM).  The primary reaction mixture was diluted ten-fold to initiate 
the secondary reaction, which contained NADPH (1 mM) and (S)-warfarin (4 μM).  (S)-
warfarin 7-hydroxylation activity in the presence of vehicle control (0.75% methanol, v/v) 
was 1.5 and 1.6 pmol/min/mg microsomal protein in the absence and presence, 
respectively, of NADPH.  Symbols denote means of duplicate incubations.  Open 
symbols denote observed values when NADPH was absent from the primary reaction 
mixture; solid symbols denote observed values when NADPH was present in the primary 
reaction mixture.  Curves denote nonlinear least-squares regression of observed values 
using WinNonlin (v5.0.1).    
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Table 2.1.  Comparison of IC50 values (μM) for four key flavonolignans from milk thistle 
using (S)-warfarin 7-hydroxylation as an index of CYP2C9 activity.   
Values represent the estimate ± SE. 
  
  
Enzyme Source Silybin A Silybin B Isosilybin A Isosilybin B 
 
 
Reversible inhibition experimental design 
  
HLM   18 ± 2.2 8.2 ± 1.4a  >100  74 ± 11 
 
CYP2C9*1  12 ± 0.9 6.7 ± 0.5a ND  ND 
 
CYP2C9*2  19 ± 1.7 9.3 ± 0.9a ND  ND 
 
CYP2C9*3  9.3 ± 2.0b 2.4 ± 0.6ab ND  ND 
 
  
IC50 shift experimental design 
  
HLM (-NADPH)c 18 ±0.7 7.8 ± 0.5 ND  ND 
  
HLM (+NADPH)d 17 ± 0.7 7.9 ± 0.9 ND  ND 
    
  
aSignificantly different than the IC50 for silybin A (p<0.05, Student’s t-test of two 
independent samples). 
bSignificantly different than the IC50 obtained with HLM, CYP2C9*1, and CYP2C9*2 
(p<0.05, 1-way ANOVA, followed by Tukey’s test) for a given inhibitor. 
cNADPH was absent during the primary incubation. 
dNADPH was present during the primary incubation.
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Chapter 3 
 
Toward a Predictive Herb-Drug Interaction Framework: 
Evaluation of Milk Thistle Extracts and Eight Purified Constituents as CYP3A4/5 
Inhibitors 
 
Overview 
Despite increasing recognition of untoward interactions between herbal products 
and conventional medications, a standard system for prospective assessment of herb-
drug interactions remains elusive. This information gap was addressed by evaluating the 
drug interaction liability of the model herbal product milk thistle (Silybum marianum) with 
the CYP3A4/5 probe substrate midazolam. The inhibitory effects of commercially 
available milk thistle extracts and purified constituents on midazolam 1’-hydroxylation 
were screened using human liver and intestinal microsomes. Relative to vehicle, the 
extract silymarin and purified constituents silybin A, isosilybin A, isosilybin B, and 
silychristin at 100 μM demonstrated >50% inhibition in at least one microsomal 
preparation, prompting IC50 determination. The IC50s for isosilybin B and silychristin were 
~60, and 90 μM, respectively, whereas those for the remaining constituents were >100 
μM. Extracts and constituents that contained the 1,4-dioxane moiety demonstrated a 
>1.5-fold shift in IC50 when tested as potential mechanism-based inhibitors. The semi-
purified extract, silibinin, and the two associated constituents (silybin A, silybin B) 
demonstrated mechanism-based inhibition of recombinant CYP3A4 activity, showing 
similar kinetics (KI ~100 μM; k,inact ~0.20 min
-1). Given that milk thistle extracts have been 
administered in gram quantities, silybin A and silybin B could achieve concentrations in 
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the gut near the KI, providing a basis for clinical evaluation of the drug interaction liability 
of milk thistle with CYP3A substrates. Application of this herb-drug interaction evaluation 
framework to other herbal products may assist clinical decision-making and facilitate 
development of guidelines for quantitative prediction of clinically relevant interactions.  
  
71 
 
Introduction 
An estimated 20% of adults in the US acknowledge taking herbal products (Bent, 
2008), with nearly 70% failing to inform their conventional medical practitioner (Gardiner 
et al., 2006; Kennedy et al., 2008). An herbal product that inhibits one or more drug 
metabolizing enzymes can perpetrate untoward interactions with conventional 
medications (Hu et al., 2005; Izzo and Ernst, 2009). Prominent among these enzymes 
are the cytochromes P450 (P450s). Inhibition of P450 activity by the herbal product can 
reduce “victim” drug clearance, leading to higher systemic drug concentrations and the 
potential for adverse effects and toxicity. Dietary substances, including herbal products, 
are not regulated in the same manner as drug products. Consequently, herbal product 
drug interaction liability is not evaluated routinely prior to marketing. This information gap 
prevents both clinicians and consumers from making informed decisions about the risk 
of adding herbal products to pharmacotherapeutic regimens. 
Despite increasing recognition of potential untoward interactions between drugs 
and herbal products, a standard system for prospective assessment of the drug 
interaction liability of herbal products remains elusive. One approach to developing such 
a system is to examine a well-characterized herbal product using traditional drug-drug 
interaction (DDI) predictive tools. Milk thistle is a top-10 selling herbal product in the US 
(Blumenthal et al., 2012) used predominately to self-treat hepatic disorders, particularly 
hepatitis C (Kroll et al., 2007; Post-White et al., 2007; Seeff et al., 2008). Milk thistle 
represents an ideal model herbal product due to the following key properties: high sales 
numbers (12.8 million dollars in 2011) indicate that a large number of consumers are at 
risk for milk thistle-drug interactions (Blumenthal et al., 2012); individual constituents 
have been identified, isolated, and scaled-up to quantities sufficient for  in vitro DDI 
evaluation (Kim et al., 2003; Graf et al., 2007; Monti et al., 2010; Sy-Cordero et al., 
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2012); and the literature indicates inconsistent in vitro-in vivo extrapolation of extant 
studies (Gurley et al., 2004; Gurley et al., 2006; Han et al., 2009).  
 Commercial preparations of milk thistle [Silybum marianum (L.) Gaertn.] include 
the crude extract silymarin, consisting of at least seven flavonolignans (Fig. 3.1), the 
flavonoid taxifolin, and fatty acids, and the semi-purified extract silibinin, consisting of the 
most prevalent flavonolignans (silybin A and silybin B). These extracts have been shown 
to inhibit the activity of several P450s in vitro, both reversibly (e.g., CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4/5) (Beckmann-Knopp et al., 2000; Zuber et al., 2002; 
Etheridge et al., 2007; Doehmer et al., 2008; Brantley et al., 2010) and irreversibly (e.g., 
CYP2C9, CYP3A4) (Sridar et al., 2004). Translation to the clinic, however, has been 
inconsistent. For example, two healthy volunteer studies demonstrated no interaction 
between the CYP3A4/5 probe substrate midazolam and one silymarin product (Gurley et 
al., 2004; Gurley et al., 2006), whereas another study demonstrated a different silymarin 
product to increase significantly the systemic exposure to the CYP2C9/3A4/5 substrate 
losartan (Han et al., 2009). Explanation of these in vitro-in vivo disconnects requires 
rigorous characterization of the CYP3A4/5 inhibition properties of individual constituents, 
as well as commercial preparations.  
CYP3A4/5 is responsible for the oxidative metabolism of nearly 50% of the top 
200 prescribed medications (Wienkers and Heath, 2005) and is expressed in both the 
intestine and liver (Thummel et al., 1996). Following oral administration of milk thistle, 
intestinal CYP3A4/5 likely will be exposed to higher concentrations of the constituents 
compared to hepatic CYP3A4/5. This difference was demonstrated by the nearly 60-fold 
higher mean (± SD) concentration in intestinal relative to hepatic tissue in cancer 
patients administered 1.4 g silibinin (140 ± 170 vs. 2.5 ± 2.4 μM) (Hoh et al., 2006). Such 
high intestinal concentrations could reduce markedly the intestinal first-pass metabolism 
of susceptible CYP3A4/5 substrates, thereby increasing systemic drug exposure. Using 
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milk thistle as an model herbal product, the objectives of this study were to (1) assess 
the interaction liability of individual constituents towards CYP3A4/5 activity, (2) prioritize 
constituents for further evaluation, and (3) develop a framework to explain in vitro-in vivo 
disconnects and predict future herb-drug interactions. This information ultimately may 
permit clinicians and consumers to gauge the impact of adding herbal products to 
pharmacotherapeutic regimens.  
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Materials and Methods 
Chemicals and reagents. Human liver (pooled from 50 donors, mixed gender) 
and intestinal (pooled from 18 donors, mixed gender) microsomes (HLMs, HIMs) were 
purchased from Xenotech, LLC (Lenexa, KS). Baculovirus insect cell-expressed 
CYP3A4 (rCYP3A4), supplemented with cDNA-expressed reductase and cytochrome b5, 
was purchased from BD Biosciences (San Jose, CA). Midazolam, 1’-hydroxymidazolam, 
alprazolam, silibinin, ketoconazole, NADPH, glutathione, superoxide dismutase (SOD), 
catalase, 5,5-dimethyl-1-pyrroline-n-oxide (DMPO), DMSO, HPLC-grade water, 
methanol, ammonium acetate, and 1-propanol were purchased from Sigma-Aldrich (St. 
Louis, MO). 6’,7’-Dihydroxybergamottin (DHB) was purchased from Cayman Chemical 
(Ann Arbor, MI). Silymarin was obtained from Euromed S.A. (Barcelona, Spain). Silybin 
A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin, and taxifolin 
were purified as described previously (Graf et al 2007); all milk thistle constituents were 
>97% pure as determined by high-performance liquid chromatography.  
 Evaluation of the stability of individual milk thistle constituents. Stability in 
potassium phosphate buffer. Each constituent was dissolved in DMSO to yield a 100 
mM solution. Each solution was diluted in potassium phosphate buffer (0.1 M, pH 7.4), 
supplemented with MgCl2 (3.3 mM), to yield a final concentration of 100 µM. Solutions 
were placed immediately into a heated (37°C) auto-sampler, and aliquots (0.3 µL) were 
collected serially from 0-1440 min and analyzed via UPLC-UV (described below). 
Metabolic lability of selected constituents. Silybin A, silybin B, isosilybin A, and isosilybin 
B were added to potassium phosphate buffer as described above with the addition of 
HLMs (0.05 mg/mL). Incubation mixtures were placed on a dry heat block and 
equilibrated for 5 min. Reactions were initiated with the addition of NADPH to yield a 
final concentration of 1 mM. Aliquots (100 μL) were removed from 0-60 min, and 
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reactions were terminated with 2 volumes of ice-cold acetonitrile. Each constituent was 
quantified by UPLC-UV (described below). 
Analysis of incubations for milk thistle constituents. Constituents were 
quantified with an Acquity UPLC system (Empower 2 software; Waters Corp., Milford, 
MA) at a flow rate of 0.80 (stability study) or 0.75 (lability study) mL/min using an Acquity 
binary solvent manager and an Acquity HSS-T3 column (1.8 μm, 2.1 × 50 mm; Waters 
Corp.). The elution gradient for the stability study ranged from 10:90 to 40:60 
methanol:water over 0.45 minutes, then from 40:60 to 55:45 over 1.5 minutes. The 
elution gradient for the lability study ranged from 40:60 to 55:45 methanol:water over 2 
minutes. Signals were monitored at UV 288 nm using an Acquity PDA detector, and the 
volume injected was 0.3 (stability study) or 7.5 (lability study) μL by an Acquity sample 
manager. 
Evaluation of milk thistle constituents as inhibitors of CYP3A4/5 activity. 
The inhibitory effects of silymarin, silibinin, and individual constituents on midazolam 1’-
hydroxylation activity were evaluated using HLMs, HIMs, and rCYP3A4. Midazolam and 
ketoconazole were dissolved in methanol to yield 10 mM and 1 mM solutions, 
respectively. Milk thistle constituents were dissolved in DMSO to yield a 200 mM 
solution. NADPH was prepared fresh in potassium phosphate buffer to yield a 4 mM 
solution. Under all experimental conditions, the amount of 1’-hydroxymidazolam formed 
was linear with respect to incubation time and concentration of microsomal or rCYP3A4 
protein (data not shown). Initial testing. Incubation mixtures consisted of HLMs or HIMs 
(0.05 mg/mL protein), midazolam (4 μM), milk thistle constituent/extract (1, 10, or 100 
μM), and potassium phosphate buffer. Control mixtures contained 0.1% (v/v) DMSO in 
place of milk thistle constituent/extract. As a positive control for CYP3A4/5 inhibition, 
mixtures contained ketoconazole (1 μM) in place of milk thistle constituent/extract. The 
mixtures were equilibrated in a dry heat block at 37°C for 5 min before initiating the 
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reactions with NADPH (1 mM final concentration) to yield a final volume of 200 μL. After 
2 (HLMs) or 4 (HIMs) min, reactions were terminated with 2 volumes of ice-cold 
acetonitrile containing 20 µg/mL alprazolam as the internal standard. After centrifugation 
(1350 x g for 10 min at 4C), supernatants were analyzed for 1’-hydroxymidazolam by 
HPLC-MS/MS as described previously (Wang et al., 2007; Ngo et al., 2009). Individual 
constituents demonstrating ≥50% inhibition in either microsomal preparation were 
selected for further evaluation. Screening of constituents as reversible inhibitors of 
CYP3A4/5 activity in HLMs and HIMs. Incubation mixtures were prepared as described 
above, only milk thistle constituent/extract concentrations ranged from 0.10-200 μM. 
Reaction mixtures were processed and analyzed for 1’-hydroxymidazolam as described 
above. Screening of constituents as metabolism-dependent inhibitors of CYP3A4/5 
activity in HLMs, HIMs, and rCYP3A4. IC50 shift experiments (Obach et al., 2007) were 
used to screen milk thistle constituents and extracts as potential mechanism-based 
inhibitors of CYP3A4/5 activity. Primary incubation mixtures consisting of HLMs, HIMs 
(0.25 mg/mL), or rCYP3A4 (20 pmol/mL), milk thistle constituent/extract (0-1000 μM), 
and potassium phosphate buffer were equilibrated at 37°C for 5 min before initiating 
reactions with NADPH (1 mM). Control reactions were identical except NADPH was 
replaced with potassium phosphate buffer. After 15 min, an aliquot (40 μL) was removed 
and diluted 5-fold into a secondary incubation mixture containing midazolam (4 μM) and 
NADPH (1 mM). After 2 (HLMs) or 4 (HIMs and rCYP3A4) min, the secondary reactions 
were terminated and processed as described above. Individual constituents 
demonstrating a >1.5-fold shift in IC50 were selected for further analysis. Effect of 
nucleophilic trapping agents and reactive oxygen species scavengers on CYP3A4/5 
inactivation in HLMs. Primary mixtures consisted of HLMs (0.25 mg/mL), silybin A (0, 30, 
or 100 μM), potassium phosphate buffer, and trapping agent [DMPO (1 mM), SOD 
(1,000 U/mL), glutathione (2 mM), or catalase (5,000 U/mL)]. The mixtures were 
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equilibrated at 37°C for 5 min before initiating reactions with NADPH (1 mM). Control 
reactions were identical except NADPH was replaced with potassium phosphate buffer. 
Reactions proceeded as described for the IC50 shift experiment. Determination of 
mechanism-based inhibition kinetics. Time- and concentration-dependent inhibition of 
CYP3A4 was assessed as described previously (Paine et al., 2004). Briefly, primary 
incubation mixtures consisting of rCYP3A4 (0.2 nmol/mL), milk thistle constituent/extract 
(0-200 μM), and potassium phosphate buffer were equilibrated at 37°C for 5 min before 
initiating the primary reactions with NADPH. As a positive control for mechanism-based 
inhibition, incubation mixtures contained DHB (5 μM) in place of milk thistle 
constituent/extract (Paine et al., 2004). At designated times (0-15 min), an aliquot (4 μL) 
was removed and diluted 50-fold into a secondary reaction mixture containing 
midazolam (8 μM) and NADPH (1 mM). The secondary reactions were terminated and 
processed as described for the reversible inhibition experiments.  
 Data analysis. Determination of apparent IC50. The apparent IC50 of milk thistle 
constituent/extract was recovered according to previously published methods (Brantley 
et al., 2010). Briefly, an initial estimate was determined by visual inspection of the 
velocity of 1’-hydroxymidazolam formation versus the natural logarithm of milk thistle 
constituent/extract concentration data. Apparent IC50 was recovered by fitting equation 1 
or 2 to untransformed data using WinNonlin (version 5.3; Pharsight, Mountain View, CA): 
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where v denotes the velocity of 1’-hydroxymidazolam formation, v0 denotes the initial 
velocity of 1’-hydroxymidazolam formation, I denotes the concentration of milk thistle 
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constituent/extract, and h denotes the Hill coefficient. The best-fit equation was 
assessed from visual inspection of the observed versus predicted data, randomness of 
the residuals, Akaike information criteria, and SEs of the parameter estimates. 
 Determination of KI and kinact. Mechanism-based inhibition (MBI) parameters were 
recovered according to previously published methods (Paine et al., 2004; Obach et al., 
2007). Briefly, the natural logarithm of the percentage of CYP3A4 activity remaining was 
plotted as a function of primary reaction time. The apparent inactivation rate constant 
(kinact,app) for each inhibitor concentration was determined from the slope of the initial 
mono-exponential decline in activity. Initial estimates of KI and kinact were obtained from a 
Kitz-Wilson plot. Final parameter estimates were obtained by nonlinear least-squares 
regression using equation 3: 
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where kzero is the rate of CYP3A4 inactivation in the absence of inhibitor. The efficiency 
of inactivation was calculated as the ratio of kinact to KI. 
Statistical analysis. Data are presented as means ± SDs of triplicate 
determinations unless indicated otherwise. Enzyme kinetic parameters are presented as 
the estimates ± SEs. All statistical comparisons were made according to previously 
published methods (Brantley et al., 2010). In brief, concentration-dependent inhibition of 
individual flavonolignans was evaluated by a one-way ANOVA; post-hoc comparisons 
were made using Tukey’s test when an overall significance resulted. Statistical 
differences between calculated IC50 values were evaluated by a Student’s t-test of two 
independent samples. A p<0.05 was considered significant for all statistical tests.  
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Results 
Selected milk thistle constituents are metabolically stable in HLMs for up to 
15 min. All tested constituents were stable (>95% remaining) for 1 h at 37°C in 
potassium phosphate buffer (data not shown). Metabolic stability experiments 
determined the optimal primary incubation time such that inhibitor depletion would be 
≤20%. All constituents at 10 μM demonstrated ≥50% oxidative depletion by 60 min (Fig. 
3.2). Isosilybin A was the least stable, showing 40% depletion by 10 min, whereas the 
remaining constituents were depleted by <10%. At 100 μM, silybin A was slightly more 
stable than the other constituents, (~40% vs. 50% depletion by 60 min). Isosilybin A was 
the least stable, showing 30% depletion by 10 min, whereas the remaining constituents 
were depleted by <10%. Based on these observations, the primary incubation time of 
the metabolism- and mechanism-dependent inhibition experiments was limited to 15 
min. 
Milk thistle constituents differentially inhibit CYP3A4/5-mediated 
midazolam 1’-hydroxylation. Initial testing. All flavonolignans and the two extracts 
(silibinin, silymarin) inhibited midazolam 1’-hydroxylation in a concentration-dependent 
manner (100 vs. 10 μM) in HLMs (Fig. 3.3A) and, with the exception of isosilychristin, in 
HIMs (Fig. 3.3B). The sole flavonoid, taxifolin, showed no concentration-dependent 
inhibition with either preparation. Only silybin B (HLMs), silychristin (HIMs), and 
silydianin (HIMs) showed concentration-dependent inhibition from 10 to 1 μM (1 µM data 
not shown). With HLMs, silybin A at 100 μM was the most potent, followed by silymarin, 
isosilybin B, and isosilybin A (Fig. 3.3A); with HIMs, silymarin at 100 μM was the most 
potent, followed by isosilybin A, isosilybin B, and silychristin (Fig. 3.3B). Based on >50% 
inhibition at 100 µM in at least one microsomal preparation, silybin A, isosilybin A, 
isosilybin B, and silychristin were selected for IC50 determination. Additionally, based on 
the high concentrations (>140 µM) observed in enterocytes following silibinin 
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administration to human subjects (Hoh et al 2006), silybin B and silibinin were selected 
for further evaluation. Reversible inhibition. With both HLMs and HIMs, isosilybin B was 
the most potent constituent, followed by silychristin, silybin B, and silybin A (Table 3.1). 
Because isosilybin A was not soluble at concentrations >100 µM, a complete IC50 curve 
could not be recovered. IC50 shift. The IC50 for silybin A, silybin B, and silibinin was 73-
98% lower in the presence compared to the absence of NADPH in the primary 
incubation (Table 3.2). rCYP3A4 was more sensitive to inhibition than HLMs and HIMs 
(Table 3.2, Fig. 3.4). The IC50 for silychristin did not decrease in either HLMs or HIMs 
(Table 3.2), precluding further evaluation of this constituent. Reactive species 
scavengers did not ameliorate the NADPH-dependent increase in potency of silybin A 
towards CYP3A4/5 activity (Fig. 3.5).  
Silybin A, silybin B, and silibinin demonstrate mechanism-based 
inactivation of rCYP3A4 activity. The time- and concentration-dependent inhibition of 
rCYP3A4 activity by silybin A, silybin B, and silibinin was evaluated to derive 
mechanism-based inhibition kinetics (Fig. 3.6). Because the rate of inactivation for 
silybin B at 200 µM deviated from linearity (Fig. 3.6B), these data were excluded from 
further analysis. The kinetics were similar between silybin A and silybin B; the kinetics of 
the 1:1 mixture of silybin A and silybin B (silibinin) were similar to those recovered for the 
single constituents (Table 3.3).  
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Discussion 
Herb-drug interactions are a growing concern in clinical practice as consumers 
turn increasingly to herbal products as a means to self-treat various conditions. Despite 
increasing recognition of these potential untoward interactions, a standard system for 
prospective assessment of the drug interaction liability of herbal products remains 
elusive. Milk thistle was selected as a model herbal product based on the well-
characterized nature, market share, and clinical relevance. Milk thistle extracts have 
been reported to inhibit P450 activity in vitro (Beckmann-Knopp et al., 2000; Zuber et al., 
2002; Doehmer et al., 2008); however, translation to the clinic has been inconsistent, 
particularly with CYP3A4/5-mediated interactions (Gurley et al., 2004; Gurley et al., 
2006; Han et al., 2009). Taken together, inhibition of CYP3A4/5 by single constituents 
was evaluated to address these in vitro-in vivo disconnects, as well as to develop a 
framework for prospective assessment of herb-drug interactions. 
As demonstrated previously with CYP2C9 activity ((S)-warfarin 7-hyroxylation) 
(Brantley et al., 2010), milk thistle constituents differentially inhibited CYP3A4/5 activity 
(midazolam 1’-hydroxylation) (Fig. 3.3). The crude extract silymarin was consistently one 
of the most potent inhibitors of CYP3A4/5 activity in microsomal preparations. Among 
single constituents, the relatively less abundant isosilybin A and isosilybin B were two of 
the more potent inhibitors in both HLMs and HIMs (Fig. 3.3). Inhibitory kinetic 
parameters were recovered for isosilybin B, whereas  metabolic lability (Fig. 3.2) and 
insolubility above 100 µM precluded recovery of these parameters for isosilybin A. 
Inhibition of midazolam 1’-hydroxylation in HLMs by silymarin at 100 µM (47%) was 
comparable to that by silymarin at approximately 50 µM (43%) in a previous study 
(Etheridge et al., 2007). With microsomes, silibinin was a more potent inhibitor of both 
nifedipine dehydrogenation (IC50, 27-60 µM) (Zuber et al., 2002) and testosterone 6β-
hydroxylation (IC50, 50 µM) (Jancova et al., 2007) compared to midazolam 1’-
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hydroxylation (IC50, 67-120 µM). Substrate-dependent inhibition potencies are well-
documented for CYP3A4 due to multiple substrate binding domains (Schrag and 
Wienkers, 2001; Galetin et al., 2003). As midazolam was the only substrate tested in the 
current work, the reversible inhibition kinetics for the individual milk thistle constituents 
can be extrapolated only to CYP3A4/5 substrates that bind to the benzodiazepine 
binding domain. In addition, the extent of inhibition by silymarin at 100 µM was greater 
than expected assuming additive inhibition by flavonolignans in aggregate (Fig. 3.3), 
suggesting that milk thistle flavonolignans may be synergistic inhibitors of CYP3A4/5. 
Further evaluation is needed to determine the extent, as well as clinical implications, of 
this potential synergism. 
With the exception of silychristin, all constituents and both extracts demonstrated 
mechanism-based inhibition (MBI) of CYP3A4/5 activity in HLMs and HIMs, as 
evidenced by a >1.5-fold shift in IC50 (Berry and Zhao, 2008). The KI for silibinin in the 
current work (110 μM) was within, whereas the kinact (0.20 min
-1) was roughly three times 
faster, than corresponding parameters reported using the CYP3A4/5 substrates 7-
benzyloxy-4-(trifluoromethyl) coumarin (32 µM and 0.06 min-1) and testosterone (132 µM 
and 0.08 min-1) (Sridar et al., 2004). The difference in kinact may reflect different enzyme 
sources (recombinant vs. reconstituted CYP3A4). Inactivation of CYP3A4 activity in 
rCYP3A4 was rapid, occurring within the 2-4 min incubation times for the reversible 
inhibition experiments. As such, some inactivation would be expected under these 
conditions; however, the presence of midazolam should mitigate inactivation through 
substrate protection (Silverman and Daniel, 1995).  
The major oxidative metabolite of silibinin is reported to be an O-demethylated 
product produced by CYP2C8 and CYP3A4 (Jancova et al., 2007). Further oxidation of 
the resulting catechol could create a reactive 1,2-benzoquinone moiety. However, 
inactivation by this mode was unlikely, as MBI was not observed with compounds 
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containing either the catechol (taxifolin) (data not shown) or the 2-methoxyphenol 
(silychristin) moiety (Fig. 3.1, Table 3.2). Unlike the 2-methoxyphenol- or catechol-
containing constituents, only constituents testing positive for MBI contained a 1,4-
dioxane moiety (Fig. 3.1). Oxidation of this region may create reactive oxygen species 
capable of inactivating CYP3A4. Since inactivation was not abrogated by the trapping 
agents, the inactivating species exerted their effect before leaving the CYP3A4 active 
site. If this proposed mode of MBI is verified, this chemical moiety may be considered an 
addition to the list of structural alerts (Kalgutkar et al., 2007). 
The clinical interaction potential for mechanism-based inhibitors is higher than 
that for reversible inhibitors, as restoration of P450 activity is dependent upon de novo 
protein synthesis, rather than removal of the offending molecule(s) (Watanabe et al., 
2007). MBI has been hypothesized as the only means by which fruit juices can elicit 
clinically significant interactions with CYP3A4/5 substrates (Hanley et al., 2012). The 
maximum rate of CYP3A4 inactivation by silibinin was roughly half that reported for the 
mechanism-based inhibitor in grapefruit juice, DHB (0.20 vs. 0.41 min-1) (Paine et al., 
2004). The KI for silybin A and silybin B was approximately one hundred times that for 
DHB (~100 vs. 1.1 µM). Thus, at equivalent exposures, DHB will inactivate CYP3A4 
more efficiently than the milk thistle constituents (370 vs. ~2 µl/min/pmol). However, 
enteric concentrations as high as 140 µM have been reported following administration of 
1.4 g/day of silibinin (Hoh et al., 2006), albeit with large between-subject variability 
(120% CV). At doses this high, clinically relevant inactivation of CYP3A4/5 might be 
anticipated, even if only limited to the intestine.  
Historically noted for putative hepatoprotective effects, self-administration of milk 
thistle products is popular among hepatitis C patients, in which an estimated 33% have 
used milk thistle as part of their therapeutic regimen (Seeff et al., 2008). These patients 
also may have an increased plasma exposure to milk thistle flavonolignans due to 
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impaired hepatic function (Schrieber et al., 2008). The disease-related decrease in 
hepatic function alone could put these patients at increased risk for metabolic DDIs. 
Adding milk thistle products may provide an additional insult rather than the desired 
hepatoprotective effect.  
In summary, herb-drug interaction predictions are challenging due to the 
multitude of bioactive constituents typically composing herbal products. As such, 
identification of individual perpetrators is necessitated. The current work outlines a 
framework to facilitate prospective evaluation of herb-drug interaction potential using 
milk thistle as a model herbal product. Of the eight constituents tested, this approach 
identified two constituents, silybin A and silybin B, which may perpetrate interactions via 
MBI of CYP3A4/5 activity. Intestinal concentrations of these constituents could achieve 
those near the KI (~100 μM), particularly with gram doses of silibinin that have been 
tested in patient populations. Clinical evaluation at these higher doses is needed to rule 
out an interaction liability with CYP3A4/5 substrates. Refinement and application of this 
framework to other herbal products ultimately may assist clinicians and consumers to 
make informed decisions about the consequences of adding an herbal product to 
conventional pharmacotherapeutic regimens.  
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Legends to Figures 
Fig. 3.1. Structures of flavonolignans and flavonoid (taxifolin) from milk thistle. 
Fig. 3.2. Metabolic lability of selected milk thistle constituents in human liver 
microsomes. Microsomes (0.05 mg/mL) were incubated with silybin A (solid circle), 
silybin B (solid diamond), isosilybin A (open circle) or isosilybin B (open diamond) at 10 
or 100 µM in potassium phosphate buffer. Incubations were initiated with NADPH (1 
mM) and quenched at designated times. Symbols and error bars denote means and 
SDs, respectively, of triplicate incubations. 
Fig. 3.3. Inhibitory effects of flavonolignans on midazolam 1’-hydroxylation activity in 
human liver microsomes (A) and human intestinal microsomes (B). Microsomes (0.05 
mg/mL) were incubated with midazolam (4 µM) and flavonolignan (10 or 100 µM; grey 
and black bars, respectively) for 2 (HLMs) or 4 (HIMs) min. Reactions were initiated with 
NADPH (1 mM). Midazolam 1’-hydroxylation activity in the presence of vehicle control 
[0.1% (v/v) DMSO] was 800 ± 40 pmol/min/mg or 280 ± 16 pmol/min/mg microsomal 
protein for HLMs and HIMs, respectively. Bars and error bars denote means and SDs, 
respectively, of triplicate incubations. 
Fig. 3.4. IC50 shift plot for silybin A, silybin B, and silibinin. Human liver microsomes (A), 
human intestinal microsomes (B), and cDNA expressed CYP3A4 (C) were incubated 
with silybin A (circles), silybin B (diamonds) or silibinin (squares) (0.1-200 µM) in the 
presence (open symbols) or absence (solid symbols) of NADPH (1 mM). The primary 
reaction mixture was diluted 5-fold to initiate the secondary reaction, which contained 
NADPH (1 mM) and midazolam (4 µM). Midazolam 1’-hydroxylation activity in the 
presence of vehicle control [(0.1% (v/v) DMSO)] was 2000 ± 90 pmol/min/mg (HLMs), 
350 ± 10 pmol/min/mg (HIMs), and 7.9 ± 1.0 pmol/min/pmol (rCYP3A4). Symbols and 
error bars denote means and SDs, respectively, of triplicate incubations. Open symbols 
denote observed data when NADPH was present in the primary incubation; solid 
86 
 
symbols denote observed data when NADPH was absent in the primary incubation. 
Curves denote nonlinear least-squares regression of observed data using WinNonlin 
(version 5.3). 
Fig. 3.5. Effect of traditional reactive species scavengers. Human liver microsomes were 
incubated for 15 min with silybin A (100 µM) and traditional reactive species scavengers 
in the presence or absence of NADPH. The primary reaction mixture was diluted 5-fold 
to initiate the secondary reaction, which contained NADPH (1 mM) and midazolam (4 
µM). Midazolam 1’-hydroxylation activity in the presence of vehicle control [(0.1% (v/v) 
DMSO] was 1700 ± 46 pmol/min/mg microsomal protein. With the exception of 
glutathione and catalase (duplicate incubations), bars and error bars denote means and 
SDs, respectively, of triplicate incubations.  
Fig. 3.6. Time- and concentration-dependent plot of CYP3A4/5 activity. cDNA expressed 
CYP3A4 was incubated with silybin A (A), silybin B (B), and silibinin (C) (0-200 µM). The 
primary reaction mixture was diluted 50-fold to initiate the secondary reaction, which 
contained NADPH (1 mM) and midazolam (8 µM), at designated times. Symbols denote 
means of duplicate incubations. Lines denote linear regression of the initial mono-
exponential decline in activity. The inset depicts the rate of CYP3A4 inactivation as a 
function of inhibitor concentration. Symbols denote observed inactivation rates at each 
inhibitor concentration. Curves denote nonlinear least-squares regression of observed 
values using WinNonlin (version 5.3). 
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Chapter 4 
 
Physiologically-Based Pharmacokinetic Interaction Modeling Framework  
for Quantitative Predictions of Metabolic Herb-Drug Interactions 
 
Overview 
Herb-drug interaction predictions remain challenging. Physiologically-based 
pharmacokinetic (PBPK) modeling was used to improve prediction accuracy and assist 
clinical trial design of potential herb-drug interactions using the semi-purified milk thistle 
preparation, silibinin, as an exemplar herbal product. Interactions between silibinin 
constituents and the probe substrates warfarin (CYP2C9) and midazolam (CYP3A) were 
modeled. A low silibinin dose (160 mg/day x 14 days) was predicted to increase 
midazolam AUC by 1%, as corroborated with external data; a higher dose (1440 mg/day 
x 7 days) was predicted to increase midazolam and (S)-warfarin AUC by 5% and 4%, 
respectively. Clinical evaluation confirmed minimal interactions between silibinin and 
both midazolam and (S)-warfarin (9 and 13% increase in AUC, respectively). (R)-
warfarin AUC was decreased (by 15%) but unlikely to be clinically relevant. Application 
of this PBPK modeling approach to other herb-drug interactions could facilitate 
development of guidelines for quantitative prediction of clinically relevant interactions 
and aid in informed decisions about adding herbal products to conventional 
pharmacotherapy. 
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Introduction 
Current US FDA oversight of herbal products does not include evaluation of drug 
interaction liability prior to marketing. Consequently, herb-drug interactions typically are 
investigated following case reports of adverse events. Although interactions caused by 
St. John’s Wort are well-publicized (Gurley et al., 2012; Hermann and von Richter, 
2012), consumers remain hesitant to discuss herbal product usage with health care 
practitioners. An estimated 20% of adults in the US consume herbal products (Bent, 
2008), and less than one-third inform their health care practitioners (Gardiner et al., 
2006; Kennedy et al., 2008). Taken together, herbal products remain understudied 
perpetrators of potential drug interactions.  
Drug interaction liability assessment is more challenging for herbal products than 
conventional drugs because unlike drug products, herbal products typically are mixtures 
of bioactive constituents that vary substantially between preparations (de Lima 
Toccafondo Vieira and Huang, 2012; Gurley, 2012; Hermann and von Richter, 2012). 
Compounding this complexity is the often scant knowledge of the specific causative 
constituents or the systemic exposure of such constituents. Due to incomplete 
absorption and extensive pre-systemic clearance, herbal products may only reach 
sufficient concentrations in the intestine and liver to inhibit first-pass metabolism of 
sensitive substrates (Paine and Oberlies, 2007). Isolation and purification of individual 
constituents permit testing of herbal products akin to that for conventional drugs. Recent 
drug-drug interaction (DDI) guidelines suggest dynamic modeling and simulation 
approaches to predict complex interactions (US FDA, 2012; European Medicines 
Agency, 2012). Extension of this approach to herb-drug interactions is a logical step to 
facilitate prospective evaluation of such interactions. As with DDIs (Fahmi et al., 2009; 
Huang and Rowland, 2012), physiologically-based pharmacokinetic (PBPK) modeling 
may be used to improve predictions of herb-drug interaction liability. In vitro kinetic 
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parameters for individual constituents, as well as estimates of systemic constituent 
exposure, are needed to develop robust models. 
Milk thistle preparations are top-ten selling herbal products in the US (Blumenthal 
et al., 2011). The crude extract, silymarin, contains at least seven flavonolignans and 
one flavonoid (Kroll et al., 2007). The semi-purified product silibinin contains roughly a 
1:1 mixture of the flavonolignans silybin A and silybin B and represents an exemplar 
herbal product for initial model development. First, silybin A and silybin B have been 
purified in quantities sufficient to recover requisite in vitro parameters (Graf et al., 2007; 
Monti et al., 2010). Second, in vitro studies have demonstrated both reversible and 
irreversible inhibition of the key drug metabolizing enzymes CYP2C9 (Zuber et al., 2002; 
Sridar et al., 2004; Brantley et al., 2010) and CYP3A4 (Zuber et al., 2002; Sridar et al., 
2004). Third, in vitro-in vivo extrapolation has been inconsistent (Gurley et al., 2004; 
Gurley et al., 2006; Han et al., 2009). Based on these observations, the objective of this 
study was to improve the mechanistic understanding of this herb-drug interaction using 
PBPK modeling and simulation with warfarin and midazolam as probe substrates. The 
models were evaluated through a proof-of-concept clinical study in healthy volunteers. 
Results could help develop guidelines for prospective evaluation of herb-drug interaction 
liability. 
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Methods 
PBPK model development. The base model structure was adapted from the 
literature (Bjorkman et al., 2001) (Figure 4.1), incorporating physiologic parameters 
obtained from the International Commission on Radiological Protection (ICRP) (Boecker, 
2003). Warfarin partition coefficients (Kps) (Luecke et al., 1994) and plasma protein 
binding parameters (Chan et al., 1994) were obtained from the literature (Table 4.1). The 
absorption rate constant (ka) and saturable clearance parameters (Km, Vmax) for warfarin 
were obtained by fitting the PBPK model to previously reported concentration-time 
profiles (Ngo et al., 2010). Midazolam Kps and ka were obtained from the literature 
(Langlois et al., 1987; Bjorkman et al., 2001) (Table 4.1). Intestinal and hepatic 
midazolam clearance parameters were extrapolated from in vitro experiments (Brantley 
et al., 2009) according to previously published methods (Barter et al., 2007; Obach, 
2011). Kps for silybin A and silybin B were predicted from physicochemical properties 
(Poulin et al., 2001) using GastroPlus (version 8.0; Simulations Plus Inc., Lancaster, 
CA). Silibinin plasma binding parameters were obtained from the literature (Deng et al., 
2008) and clearance parameters were generated by fitting the PBPK model to 
concentration-time data from hepatitis C patients receiving silymarin (Hawke et al., 2010) 
(Table 1). Silybin A and silybin B reversible and mechanism-based inhibition kinetic 
parameters associated with CYP2C9 and CYP3A4 were obtained from the literature 
(Brantley et al., 2010) or generated in-house (unpublished observations). Competitive 
inhibition of CYP2C9 activity by (R)-warfarin was obtained from the literature (Kunze et 
al., 1991). 
PBPK interaction model simulations. PBPK models were constructed for 
midazolam, (R)-warfarin, (S)-warfarin, silybin A, and silybin B using Berkeley Madonna 
(version 8.3; University of California at Berkeley, Berkeley, CA) with code compiled in 
MEGen (Loizou and Hogg, 2011) (version 0.5; UK Health & Safety Laboratory, Buxton, 
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UK) (Table 4.S.1). The PBPK model for perpetrator (silybin A and silybin B) and victim 
(warfarin or midazolam) were linked through the reversible or mechanism-based 
inhibition of victim substrate. Initial simulations used doses of probe substrates and milk 
thistle products as reported in previous studies. Following initial model evaluation, 
simulations were conducted with higher doses of silibinin (1440 mg/day) to determine 
the maximal expected interaction. Pharmacokinetic outcomes from the simulated profiles 
were recovered via non-compartmental analysis using Phoenix Winnonlin (version 6.3; 
Pharsight Corp., Mountain View, CA). 
Analysis of silibinin product. Siliphos® capsules (n=28) (Thorne Research, 
Dover, ID) were analyzed individually using a modification of previously described 
methods (Kim et al., 2003; Davis-Searles et al., 2005; Ladas et al., 2010) to ensure 
purity and content. The contents of each capsule was weighed and extracted with 2 mL 
of acetone. The extract was vortexed, centrifuged at 13,000 x g for 2 min, and the 
supernatant was transferred to a new vial. The pellet was extracted a second time using 
an identical method, and the acetone supernatants were combined and dried. Aliquots of 
these extracts were prepared at 10 mM (presuming a molecular weight of 482.1 g/mol) 
in DMSO (42, 43) then diluted to 100 µM in 30:70 MeOH:H2O for analysis. Samples 
were quantitated on an Acquity UPLC system with an HSS-T3 1.8 µm (2.1 x 100 mm) 
Acquity column using Empower 3 software (Waters, Milford, MA). Standards and 
Siliphos® capsule extracts were analyzed utilizing a gradient from 30:70 to 55:45 
MeOH:H2O (0.1% formic acid) over 5.0 min at a flow rate of 0.6 mL/min at 50°C, with 
peaks detected at 288 nm. 
Proof-of-Concept Clinical Study Design. Twelve healthy volunteers (six 
nonpregnant women) were enrolled in an open-label, fixed sequence crossover drug 
interaction study conducted at the UNC Clinical and Translational Research Center 
(CTRC). The study protocol was approved by the University of North Carolina Office of 
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Human Research Ethics Biomedical Institutional Review Board and the CTRC Advisory 
Committee. Eligibility to participate was based on screening evaluation and according to 
inclusion/exclusion criteria (Table 4.S.2). Written informed consent was obtained from 
each subject prior to enrollment. 
The first (control) phase consisted of administration of 10 mg warfarin 
(Coumadin®; Bristol Meyers Squibb, Princeton, NJ), 10 mg vitamin K (Mephyton®; Aton 
Pharma, Lawrenceville, NJ), and 5 mg midazolam syrup (Ranbaxy; Jacksonville, FL). 
Women of childbearing potential were administered a pregnancy test; a negative result 
was required before drug administration. Vital signs (blood pressure, temperature, 
respiratory rate, pulse, oxygen saturation) were obtained at baseline and every 15 
minutes for the first 2 hours. All subjects underwent an INR with PT. Blood (7 mL) was 
collected through an intravenous line before drug administration and at 0.25, 0.5, 1, 1.5, 
2, 3, 4, 6, 8, and 12 hours thereafter. Subjects continued to fast until after the 4-hour 
blood collection, when meals and snacks, devoid of fruit juices and caffeinated 
beverages, were provided. Subjects returned to the CTRC 24 and 48 hours post-drug 
administration for blood collection. Optimal study design simulations (Ma et al., 2004) of 
previously reported clinical data (Ngo et al., 2009) demonstrated that a 0-48 hour 
collection was an effective surrogate of the total systemic exposure (AUC0-inf) for 
warfarin. Plasma was separated from blood cells by centrifugation and stored at -80°C 
pending analysis by HPLC/MS-MS.  
Following at least 14 days of washout, the subjects received 480 mg silibinin 
(based on labeled content) three times daily for 7 days. Subjects returned on day 7 for 
concomitant administration of silibinin, warfarin, vitamin K, and midazolam. Each subject 
received his/her silibinin in a blister pack and was asked to complete a pill diary 
documenting the time of administration. Subjects were contacted at least twice during 
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the week of silibinin self-administration to monitor compliance and adverse events, which 
were graded using a validated Adverse Events Scale. 
Pharmacokinetic analysis. Pharmacokinetic outcomes were recovered by 
noncompartmental analysis using Phoenix Winnonlin (version 6.3; Pharsight Corp., 
Mountain View, CA). Concentrations below the limit of quantification were excluded. The 
terminal elimination rate constant (λz) was estimated by linear regression of the terminal 
portion of the log-transformed concentration-time profile using at least three data points. 
The terminal half-life (t1/2) was calculated as ln(2)/λz. The maximum observed 
concentration (Cmax), time to reach Cmax (tmax), and last measured concentration (Clast) 
were recovered directly from the concentration-time profile. Area under the curve from 
time zero to Clast (AUC0-last) was determined using the trapezoidal rule with linear up/log 
down interpolation. AUC0-inf was calculated as the sum of AUC0-last and the ratio of Clast to 
λz.  
Statistical analysis. All statistical analyses were conducted using SAS (version 
9.2; SAS Institute Inc, Cary, NC). The primary endpoints were the test/reference ratio of 
log-transformed AUC0-48 (warfarin) or AUC0-inf (midazolam) and Cmax (warfarin and 
midazolam) (US Food and Drug Administration, 2012; European Medicines Agency, 
2012). The two treatment groups were considered bioequivalent if the respective means 
were within 25% of each other and the calculated 90% confidence interval for the ratio of 
means lay between 0.75 and 1.33.  The sample size (n=12 evaluable subjects) was 
calculated based on 80% power to detect a 25% change in the primary outcomes with a 
Type I error of 0.05. Intra-individual variability in midazolam and warfarin AUC and 
Cmax were assumed to be approximately 20% (Kashuba et al., 1998; Kharasch et al., 
1999; Yacobi et al., 2000). Secondary outcomes such as oral clearance (Cl/F), t1/2, and 
tmax were evaluated using a paired two-tailed Student's t- test on log-transformed data or 
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Wilcoxon signed-rank test as appropriate.  A p-value <0.05 was considered statistically 
significant. 
Analysis of plasma for (R)- and (S)-warfarin and midazolam.  Concentrations 
of (R)- and (S)-warfarin and midazolam were quantified using a Sciex (Framingham, MA) 
API4000Qtrap HPLC/MS/MS triple quadrupole mass spectrometer fitted with a Turbo 
ionspray interface operated in the positive ion mode. Plasma was treated with 
acetonitrile (6 volumes) containing the internal standard warfarin-d5 (Toronto Research 
Chemicals; Toronto, Canada) or 1’-hydroxymidazolam-d4 (Cerilliant; Round Rock, TX), 
centrifuged (3000 x g), and the supernatant was injected into the HPLC-MS/MS system. 
Warfarin enantiomers were separated on a Supelco Astec Chirobiotic V 15 cm x 2.1mm 
5 micron chiral column (Sigma Aldrich; St Louis, MO) and eluted with an isocratic 
mixture consisting of 75% 5 mM ammonium acetate containing 0.01% (v/v) formic acid 
and 25% acetonitrile (flow rate, 0.4 mL/min). Midazolam was eluted with a binary 
gradient mixture consisting of 10 mM ammonium formate containing 1% (v/v) isopropyl 
alcohol and 0.1% (v/v) formic acid and methanol on a Varian Polaris C18-A 20 cm x 2.0 
mm 5 micron column (Agilent; Santa Clara, CA) (flow rate, 0.65 mL/min). Analyte 
concentration was determined by interpolation from a linear standard curve with an 
assay dynamic range of 0.5-10,000 nM for (R)- and (S)-warfarin and 0.5-5,000 nM for 
midazolam.  
Analysis of plasma for silybin A and B.  Concentrations of silybin A and silybin 
B were quantified using a Sciex mass spectrometer as described for warfarin and 
midazolam. Samples were eluted with an isocratic mixture consisting of 44% water with 
0.1% (v/v) formic acid (solvent A) and 56% methanol with 0.1% (v/v) formic acid on an 
Agilent Zorbax XDB C18 15 cm x 3.0 mm 3.5 micron column (Agilent) (flow rate, 0.7 
mL/min). Analyte concentrations were determined by interpolation from linear standard 
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curves with a dynamic range of the assay ranging from 0.5-5,000 nM for both silybin A 
and silybin B. 
Analytical methods were validated according to US Food and Drug 
Administration (FDA) guidelines (US Food and Drug Administration, 2001). Inter- and 
intra-day variability for all analytes was less than 10%. 
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Results 
Modeling and simulation. PBPK model generation and evaluation. Simulated 
probe substrate concentrations closely approximated previously published 
pharmacokinetic outcomes (Table 4.2). The terminal half-life for both (R)- and (S)-
warfarin  was underestimated, whereas maximum concentration (Cmax), systemic 
exposure (AUC), and oral clearance (Cl/F) were predicted accurately. Simulated 
midazolam AUC was overestimated at the higher silibinin dose, whereas Cmax was 
underestimated at the lower silibinin dose. As anticipated, simulated silybin A and silybin 
B concentrations were less accurate than those for warfarin and midazolam. The Cmax 
for silybin A was underpredicted by roughly three-fold, whereas that for silybin B was 
underpredicted by roughly two-fold (Table 4.2). The AUC of silybin A was underpredicted 
by roughly 15%, whereas that for silybin B was overpredicted by roughly two-fold.    
Prediction of silibinin-drug interaction magnitude. Simulations of the silibinin-
warfarin interaction showed negligible changes (<5%) in all pharmacokinetic outcomes 
(Table 4.3). Likewise, simulations of a previously reported milk thistle-midazolam 
interaction (Gurley et al., 2006), assuming reversible CYP3A inhibition solely due to 
silybin A and silybin B, demonstrated negligible changes in pharmacokinetic outcomes 
(Figure 4.2). Incorporation of mechanism-based CYP3A inhibition showed a 60% and 
30% increase in midazolam AUC and Cmax, respectively (Figure 4.2). Increases of 3% 
and 6% in midazolam AUC and Cmax, respectively, were reported (Figure 4.2). 
Simulations with a higher silibinin dose (1440 mg/day) predicted a 5% increase in 
midazolam AUC when incorporating reversible inhibition and a 5-fold increase in AUC 
when incorporating mechanism-based inhibition (Table 4.3).  
Clinical evaluation. Silibinin content in test product. A single lot (#304090) of 
Siliphos® capsules was used. The capsules were labeled to contain 60 mg of silibinin 
and 120 mg of phosphatidyl choline, totaling 180 mg. The Siliphos® capsules were 
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overfilled with silibinin consistently, containing 69.1 ± 4.28 mg silibinin represented as 
30.3 ± 1.88 mg silybin A and 38.9 ± 2.39 mg silybin B. The capsules were contaminated 
slightly with the minor constituents isosilybin A (1.55 ± 0.09 mg) and isosilybin B (0.94 ± 
0.06 mg). Stability of >98% has been reported at 21 months (Ladas et al., 2010), but the 
capsules were used within six months of receipt. 
Clinical study subjects. All enrolled subjects (n=12) completed both phases of the 
study. All study drugs and silibinin generally were well-tolerated. One subject 
experienced mild gastrointestinal upset following the first dose of silibinin. The effect was 
deemed likely to be drug-related by the study physician but was transient and did not 
limit the subject’s continued participation in the study. During study visits to the CTRC, 4 
subjects (2 in both phases) reported mild headaches attributed to caffeine withdrawal. 
No INR elevations from baseline were observed following warfarin administration.  
Effects of high-dose silibinin on midazolam and warfarin pharmacokinetics. The 
effects of high-dose silibinin (1440 mg/day) were compared to baseline oral 
pharmacokinetics of midazolam and warfarin. Due to the reported mechanism-based 
inhibition of CYP3A in vitro (Sridar et al., 2004), silibinin was administered three times 
daily for 6 days prior to administration of the probe substrates. Silibinin constituents were 
not expected to accumulate during the administration period due to short reported half-
lives (<4 hour) (Wen et al., 2008). One subject demonstrated poor goodness-of-fit 
statistics for the t1/2 of both warfarin enantiomers in both phases (R
2 < 0.85). Accordingly, 
data from this subject were excluded from analysis of t1/2 and Cl/F. 
 Warfarin enantiomers were absorbed rapidly during both study phases, with 
median time to peak concentration (tmax) occurring at 1.25 and 1.5 hours for (R)- and (S)-
warfarin, respectively (Table 4.3; Fig. 4.3). Co-administration with silibinin did not alter 
the absorption of (S)-warfarin but delayed median (R)-warfarin tmax by 15 minutes. 
Relative to control, silibinin decreased the geometric mean AUC0-48 of (R)-warfarin by 
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15%. (R)-warfarin AUC decreased in all subjects, by 2-28% (Table 4.3; Fig. 4.4A). (R)-
warfarin geometric mean Cmax similarly decreased (by 17%); Cmax decreased in 10 
subjects by 12-32% (Fig. 4.4B). Silibinin increased the geometric mean AUC0-48 of (S)-
warfarin by 13%; AUC0-48 decreased in four subjects (by 6-17%) and increased in the 
remaining subjects (by 1-62%) (Table 4.3; Fig. 4.4C). In three subjects (S)-warfarin 
AUC0-48 increased to outside the no effect range (by 36-62%). (S)-Warfarin geometric 
Cmax decreased by 2%; Cmax decreased in eight subjects (by 3-16%) and increased in 
four subjects (by 8-31%) (Fig. 4.4D). The 90% confidence intervals for all warfarin 
primary outcomes lay within the no effect range (0.75-1.33) (Table 4.3). 
The rapid absorption of midazolam was unaltered by co-administration with 
silibinin, with median tmax occurring at 0.5 hours (Table 4.3; Fig. 4.3). Relative to control, 
geometric mean midazolam AUC0-inf increased by 8% following silibinin administration 
(Table 4.3; Fig. 4.4E). Except for one subject (2.3-fold increase), treatment/control ratios 
of AUC0-inf lay within the pre-defined no effect range (0.75-1.33). Relative to control, five 
subjects demonstrated marked (>50%) increases in Cmax, whereas one subject 
demonstrated a marked (>50%) decrease in Cmax. The 90% confidence interval for 
midazolam treatment-to-control ratio of AUC0-inf lay within, whereas that of Cmax extended 
above, the no effect range (Table 4.3; Fig. 4.4F). 
 The sampling strategy was not optimized for recovery of silybin A and silybin 
pharmacokinetic outcomes; as such, these outcomes were interpreted for qualitative 
rather than quantitative purposes. The median tmax of silybin A and silybin B following the 
initial administration of silibinin (3 and 3.5 hours, respectively) nearly coincided with the 
second administration of silibinin (Table 4.3; Fig. 4.3). Geometric mean Cmax for silybin A 
was nearly double that for silybin B (Table 4.3). Geometric mean t1/2 of both silybin A and 
silybin B was approximately 5 hours.  
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Discussion 
Although herbal product usage continues to increase, current US regulatory 
guidelines do not request pre-market evaluation of herb-drug interaction liability. 
Investigations into such liabilities are fraught with inconsistent results due to the lack of a 
standard system for evaluation, high compositional variation between herbal products, 
and uncertainty about causative constituents. Unlike conventional drug products, the 
relative composition of a given herbal product may vary widely depending on weather 
conditions, product collection and storage methods, and processing procedures (Paine 
and Oberlies, 2007). Accurate predictions of herb-drug interaction liability require not 
only identification and quantification of causative constituents, but also measures of 
exposure in organs with metabolic capability. Silibinin was selected as an exemplar 
herbal product due to a well-characterized composition, availability of inhibitory kinetic 
parameters from individual constituents, and disparate impact of milk thistle products on 
victim drug pharmacokinetics in previous herb-drug interaction clinical studies. A PBPK 
modeling and simulation approach was used to address the challenges inherent to 
investigation of herb-drug interaction liability. 
Warfarin is a widely used oral anticoagulant with a narrow therapeutic window. 
Warfarin is associated with a notoriously complicated pharmacotherapy due in part to 
myriad drugs and herbal products that interfere with warfarin’s metabolism or 
anticoagulant activity. As the clearance of the more pharmacologically active (S)-
enantiomer is mediated primarily by CYP2C9, inhibition of this enzyme can lead to 
increased risk of bleeding. Silymarin was shown previously to increase systemic 
exposure to the CYP2C9/3A substrate losartan (Han et al., 2009), prompting evaluation 
of the interaction potential between milk thistle and warfarin. Of the milk thistle 
constituents whose CYP2C9 interaction liability has been evaluated in vitro, silybin A 
and silybin B were the most potent (Brantley et al., 2010). These observations lead to 
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the selection of silibinin, which consists largely of these two constituents, for clinical 
evaluation.  
Relative to control, silibinin unexpectedly decreased both the geometric mean 
AUC0-last and Cmax of (R)-warfarin. Clinical manifestation of the previously reported 
CYP1A2 induction by a milk thistle extract in vitro (Doehmer et al., 2011) is consistent 
with this decrease in exposure. In contrast to the doubling of losartan exposure following 
administration of silymarin, high-dose silibinin did not increase geometric mean (S)-
warfarin exposure to a clinically relevant extent. However, increases above 33% were 
observed in three subjects, indicating that the CYP2C9 interaction potential of silibinin 
cannot be disregarded completely.  
Modeling and simulation of the silibinin-warfarin interaction demonstrated that the 
rapid clearance of the silibinin constituents precluded marked inhibition of warfarin 
clearance. Sensitivity analysis of this interaction potential demonstrated that ten-fold 
increases in silybin A or silybin B inhibition potency would lead to roughly 15% increases 
in (S)-warfarin exposure (Fig. 4.S.1). Extensive intestinal and hepatic conjugation of 
silybin A and silybin B followed by rapid elimination likely would limit the interaction 
potential to first-pass clearance of sensitive substrates. Warfarin is not sensitive to first-
pass elimination and is cleared only upon subsequent passes through the liver, at which 
time the interaction potential of silybin A and silybin B is abated. In contrast, losartan has 
a low bioavailability (33%) that is limited, in part, to first-pass elimination (Lo et al., 
1995). This observation, coupled with the differences in study population and herbal 
product tested, could explain the difference between the reported interaction with 
losartan (Han et al., 2009) and the lack of interaction with warfarin in the present study. 
Collectively, these observations suggest examination of other CYP2C9 substrates 
sensitive to first-pass elimination, such as fluvastatin, to understand fully the milk thistle-
CYP2C9 interaction potential. 
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Midazolam is a gold standard CYP3A probe substrate metabolized extensively 
by intestinal and hepatic enzymes. Inhibition of CYP3A at either site can increase 
systemic exposure to midazolam; inhibition of hepatic CYP3A also can impact (increase) 
the t1/2. Milk thistle constituents, including silybin A and silybin B, have been shown to be 
reversible and irreversible inhibitors of CYP3A activity in both human intestinal and liver 
microsomes; however, the mechanism of clinical inhibition has not been determined. 
Previous interaction studies with midazolam (Gurley et al., 2004; Gurley et al., 2006) 
have demonstrated limited interaction potential with the milk thistle product silymarin, 
albeit the doses administered were not sufficient to determine the difference between 
reversible and irreversible inhibition of CYP3A (Fig. 4.2). The ‘supratherapeutic’ silibinin 
dose in the current study was selected to provide a large range between the predicted 
interaction based on reversible and irreversible inhibition of CYP3A and to maximize the 
ability to observe a clinical interaction. The lack of an interaction observed in all but one 
subject indicated that the CYP3A interaction potential is low for silibinin and is more 
consistent with reversible inhibition than mechanism-based inhibition. As such, the 
mechanism-based inhibition observed with recombinant and purified enzymes (Sridar et 
al., 2004) likely represent false-positives due to the highly reactive nature of these 
enzyme systems, rather than indicating actual clinical liability. 
Modeling and simulation of the silibinin-midazolam interaction indicated that the 
low interaction potential is due, in part, to the decreased potency of the silibinin 
constituents toward CYP3A compared to CYP2C9. Ten-fold increases in inhibition 
potency of silybin A and silybin B toward CYP3A activity increased midazolam exposure 
by roughly 25% (Fig. 4.S.1). These observations indicated that at the predicted 
exposures, the constituents would need to be ten-fold more potent to demonstrate any 
clinically relevant interaction with CYP3A. The large predicted increase in midazolam 
exposure following mechanism-based inhibition further supported the hypothesis that 
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products with limited systemic exposure (first posed with fruit juices (Hanley et al., 
2012)) need to be mechanism-based inhibitors of CYP enzymes to demonstrate 
clinically relevant interactions. 
 The current approach is limited due to recovery of silybin A and silybin B 
clearance parameters by fitting the model to data obtained from hepatitis C patients who 
were administered a product (silymarin) that contained additional constituents not 
measured in silibinin (Hawke et al., 2010). In vitro determination of silibinin clearance 
parameters would provide a true bottom-up modeling approach and reduce complexities 
inherent to pharmacokinetic data from patients with hepatic disease. 
Prospective evaluation of herb-drug interactions, consistent with those for 
pharmaceutical agents, largely has been ignored due to substantial compositional 
variability inherent to herbal products, multiple inhibitory constituents, and varying 
inhibitory mechanisms. The PBPK interaction model developed in the current study 
permits accurate interaction potential predictions for herbal products by incorporating in 
vitro inhibition kinetic parameters and estimates of systemic exposure of individual 
constituents. Modeling of the silibinin-warfarin and silibinin-midazolam interaction 
accurately predicted minimal clinical interaction liability. Application of this framework 
with other combinations of herbal products and conventional drugs could identify 
potential clinically significant herb-drug interactions, predict the extent of those 
interactions, and ultimately help guide pharmacotherapeutic decisions. 
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Study Highlights 
What is the current knowledge on the topic? 
 Despite increasing recognition of herb-drug interactions in clinical practice, robust 
information about the causative ingredients and mechanisms underlying these 
interactions remains limited. As a consequence, evidence-based recommendations 
about adding herbal products to existing pharmacotherapeutic regimens frequently are 
nonexistent.  
What question did this study address? 
 This study addressed the utility of a PBPK modeling approach to predict the drug 
interaction liability of an herbal product. This approach was tested using the exemplar 
herbal product silibinin and the widely used cytochrome P450 probe substrates warfarin 
and midazolam. 
What this study adds to our knowledge? 
 A PBPK modeling approach accurately predicted the minimal interaction potential 
of chronic exposure to high-‘dose’ silibinin and two FDA-recommended probe 
substrates. Sensitivity analysis demonstrated that silibinin constituents are cleared too 
rapidly to influence the systemic metabolism of warfarin and that the inhibitory potency 
towards CYP3A is not sufficient for clinical interactions with midazolam.  
How this might change clinical pharmacology and therapeutics? 
 A PBPK modeling and simulation approach could facilitate prospective evaluation 
of herb-drug interactions, as well as evidence-based recommendations regarding 
addition of herbal products to conventional drug regimens. 
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Figure Legends 
Figure 4.1. Base PBPK model structure. Model structure was modified from the 
literature (Bjorkman et al., 2001). Organ weights and blood flows were obtained from 
ICRP values (Boecker, 2003). Following oral administration, drug transfer from dosing 
compartment to intestine is driven by the oral absorption rate (ka). Drug clearance (Cl) is 
mediated by metabolic processes in the intestine and liver. The pancreas and spleen 
were combined into a hybrid “organ” identified as PSP.  
Figure 4.2. Mean concentration-time profile (0-6 hours) of midazolam in 19 healthy 
volunteers following an 8 mg oral midazolam dose given alone (open symbols) or 
following a 14-day treatment with milk thistle product (solid symbols) (21). Lines denote 
PBPK model simulations of the midazolam concentration-time profile when given alone 
(grey) or with milk thistle (black). The dotted line denotes incorporation of reversible 
inhibition of CYP3A, whereas the dashed line denotes incorporation of mechanism-
based inhibition of CYP3A. Symbols and error bars denote means and SDs, 
respectively. 
Figure 4.3. Geometric mean concentration-time profile of warfarin (A), midazolam (B), 
and silibinin (C) in 12 healthy volunteers following a 10 mg oral dose of warfarin or 5 mg 
oral dose of midazolam given alone (open symbols) or following a 7-treatment with 
silibinin (solid symbols). Lines denote PBPK model simulations of the concentration-time 
profiles when the probe substrates were given alone (solid) or with silibinin (dashed). 
Symbols and error bars denote geometric means and upper limits of the 90% confidence 
interval, respectively. 
Figure 4.4. Effects of silibinin (1440 mg/day for 7 days) on the exposure (A, C, E) and 
peak concentration (B, D, F) of (R)-warfarin (A, B), (S)-warfarin (C, D), and midazolam 
(E, F) in 12 healthy volunteers following oral administration of warfarin (10 mg) and 
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midazolam (5 mg). Open symbols connected by solid lines denote individual values. 
Solid symbols connected by dashed lines denote geometric means. 
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Table 4.1. Model input parameters 
 Victim Drug Perpetrator Compound 
Parameter (R)-Warfarin (S)-Warfarin Midazolam Silybin A Silybin B 
Physicochemical/Binding      
Molecular weight 308.33 308.33 325.78 482.44 482.44 
Fraction absorbed 1.0
a
 1.0
a
 1.0
a
 0.77
b 
0.77
b 
Ka (h
-1
) 3.0
c 
3.0
c 
1.17
d 
0.50
b 
0.50
b 
Blood/plasma ratio 1.0
e 
1.0
e 
0.80
f 
0.58
b 
0.58
b 
Unbound fraction in plasma 0.006
g 
0.006
g 
0.02
f 
0.04
h 
0.04
h 
Metabolism      
Intestinal Km (µM) - - 3.7
i 
22
c 
8.5
c 
Intestinal Vmax (µmol/h) - - 1,100
i 
2,700
c 
2,600
c 
Hepatic Km (µM) - 6.5
e 
6.0
i 
54
c 
57
c 
Hepatic Vmax (µmol/h) - 260
c 
18,000
i 
2,300
c 
2,700
c 
Hepatic Clint  (l/h) 30.4
c 
- - - - 
Inhibition      
CYP2C9 Ki (µM) 6.5
j 
- - 10
k 
4.8
k 
CYP2C9 α - - - 5
k 
8
k 
CYP3A4 Ki (µM) - - - 26.5
l 
31.5
l 
CYP3A4 kinact (min
-1
) - - - 0.22
l
  0.15
l 
CYP3A4 KI (µM) - - - 100
l 
89
l 
Ka, absorption rate constant; α, affinity change of the enzyme-substrate and enzyme-
inhibitor complexes 
aAssumed 
bPredicted based on physicochemical properties 
cObtained by fitting the model to clinical data 
dKanglois et al., 1987  
eLuecke et al., 1994  
fBjorkman et al., 2001 
gChan et al., 2004  
hDeng et al., 2008 
iExtrapolated from in vitro data 
jKunze et al., 1991 
kBrantley et al., 2010 
lGenerated in-house 
 
 
 
 
 
119 
 
Table 4.2. Model evaluation 
Measure Observed (CV) Predicted 
(R)-Warfarin (5 mg)   
t½ (h) 42 (18) 29 
tmax (h) [median (range)] 2.0 (0.5-12) 1.6 
Cmax
 
(µM) 1.7 (22) 2.1 
AUC0-inf
 
(µM *h) 93 (21) 91 
Cl/F (l/h) 0.18 (21) 0.18 
(S)-Warfarin (5 mg)   
t½ (h) 32 (26) 22 
tmax (h) [median (range)] 2 (0.5-4) 1.5 
Cmax
 
(µM) 2.0 (29) 2.1 
AUC0-inf
 
(µM *h) 65 (30) 70 
Cl/F (l/h) 0.25 (31) 0.23 
Midazolam (5 mg)   
t½ (h) 2.9 (41) 3.5 
tmax (h) [median (range)] 0.5 (0.25-1.5) 0.6 
Cmax
 
(nM) 88 (44) 70 
AUC0-inf
 
(nM *h) 215 (33) 212 
Cl/F (l/h) 71 (33) 72 
Midazolam (8 mg)   
t½ (h) 4.22 (29) 3.5 
tmax (h) [mean (SD)] 0.47 (51) 0.6 
Cmax
 
(µM) 114 (49) 112 
AUC0-inf
 
(nM *h) 295 (44) 342 
Cl/F (l/h) 95.3 (35) 72 
Silybin A (92.8 mg)   
t½ (h) 1.6 1.4 
tmax (h) [median (range)] 1.5 (1-2) 1.3 
Cmax
 
(µM) 0.84 (89) 0.27 
AUC0-inf
 
(µM *h) 1.3 1.1 
Cl/F (l/h) 150 170 
Silybin B (128 mg)   
t½ (h) 1.1 1.4 
tmax (h) [median (range)] 1.5 (0.5-2) 1.1 
Cmax
 
(µM) 0.27 (120) 0.16 
AUC0-inf
 
(µM *h) 0.28 0.63 
Cl/F (l/h) 948 407 
t1/2, terminal elimination half-life; tmax, time to maximal concentration; Cmax, maximal 
concentration; AUC, area under the concentration-time curve; Cl/F, oral clearance
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Figure 4.1. PBPK model structure 
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   Figure 4.4. 
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Table 4.S.1. Inclusion and exclusion criteria 
  
 
  
Inclusion Exclusion 
Men or women between 18 and 65 years of age 
 
History or diagnosis of any significant chronic medical 
condition such as (but not limited to) diabetes mellitus, 
hepatitis B, or HIV 
Normal screening lab test results 
 
History of any allergy, hypersensitivity, or intolerance 
to warfarin, midazolam or other benzodiazepine, 
vitamin K, or milk thistle products 
Able to understand the informed consent form 
 
History of intolerance to plants in the aster family 
(daisies, thistles, ragweed, lettuce, artichoke, 
sunflower, marigold, chamomile, and echinacea), kiwi 
fruit, or soy products 
Willing to abstain from herbal products for one week prior to 
and during the study 
Baseline INR >1.5 unless approved by study 
physician 
Willing to abstain from alcohol and caffeinated beverages 
the evening prior to each study day 
Women who are pregnant or nursing 
 
History of significant medical conditions that the study 
physician believes would increase risk (e.g., bleeding 
disorders) 
 
 
Taking concomitant medications, both prescription 
and non-prescription (including herbal products), 
known to alter warfarin, midazolam, and/or vitamin K 
blood concentrations or to alter CYP2C9 or CYP3A4 
activity (women on hormonal methods of birth control 
were allowed to participate) 
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Table 4.S.2. Clinical Study Subject Characteristics 
 
Men (n=6) Women (n=6) 
Age (years), median [range] 50 [23-63] 46 [33-53] 
Weight (kg), mean (SD) 95 (19) 74 (20) 
Self-Identified Race/Ethnicity, n 
Caucasian 4 5 
African American 1 - 
Asian - 1 
Hispanic 1 - 
Concomitant medications, n 
Oral Contraceptives - 2 
Aspirin - 1 
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Supplemental Material 1.  
Methods 
PBPK model generation. PBPK models were developed to describe the 
distribution and clearance of warfarin, midazolam, and silibinin (Figure 4.1). Distribution 
between blood and tissues was assumed to be flow-limited. The following general 
equations describe the distribution and clearance of victim and perpetrator compounds 
in non-eliminating organs: 
 
i
  (
dC
i  
dt
)  
i
 (Cart    
C
i  
P
i  
) 
where Qi denotes blood flow (l/h) into tissue i, Vi denotes volume (l) of tissue i, Ci,X 
denotes concentration (µmol/l) of compound X into tissue i, Cart,X denotes arterial 
concentration of compound X, and Pi denotes partition of compound X into tissue i. 
Organs of metabolic elimination are described by the equations below. In the 
liver, Vmax,liver,X and Km,liver,X denote the hepatic Michaelis-Menten kinetic parameters for 
compound X, and fu,liver,X denotes the unbound hepatic fraction of compound X. 
 li er  (
dCli er  
dt
)  li er (Cart    
Cli er  
Pli er  
)  Clint li er 
Clint li er 
 ma  li er   (fu li er   Cli er  )
 m li er   (fu li er   Cli er  )
 
In the intestinal tract, fu,ent,X denotes the unbound enterocyte fraction of 
compound X (assumed to be 1 for all compounds), Ka,X denotes the absorption rate 
constant (1/h) of compound X, and Xdose denotes the amount (µmol) of compound X 
remaining in the dosing compartment. 
 ent  (
dCent  
dt
)  ent (Cart    
Cent  
Pent  
)  Clint ent  a    dose 
Clint ent 
 ma  ent   (fu ent   Cent  )
 m ent   (fu ent   Cent  )
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Hepatic clearance in the presence of reversible inhibition of silybin A and silybin 
B is modified to include the hepatic concentration of silybin A (Cliver,A) and silybin B 
(Cliver,B), the inhibitory potency of silybin A (Ki,A) and silybin B (Ki,B) and the parameter to 
describe the affinity change of the enzyme-substrate and enzyme-inhibitor complexes for 
silybin A (αA) and silybin B (αB) 
Clint li er re ersiblyinhibited 
 ma  li er   (fu li er   Cli er  )
 m li er   (  
C
li er A
 
i A
 
C
li er B
 
i B
) (fu Cli er  ) (  
C
li er A
αA  i A
 
C
li er B
αB  i B
)
 
Mechanism-based inhibition (MBI) of hepatic clearance is incorporated by 
multiplying the reversible inhibition equation by the ratio of active hepatic enzyme 
(ET,Liver) to basal hepatic enzyme (E0,liver). 
Clint li er  B   Clint li er re ersiblyinhibited (
    i er
    i er
) 
The active CYP3A4 enzyme pool is approximated by incorporating enzyme 
inactivation parameters (kinact and KI) for silybin A and silybin B into the steady-state 
enzyme equation, where R0 denotes the zero-order enzyme synthesis rate and kdeg 
denotes the first-order enzyme degradation rate. 
d   li er
dt
       deg    li er   
 inact A Cli er A
   A Cli er A
    li er   
 inact B Cli er B
   B Cli er B
    li er 
  
Figure 4.S.1 
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Supplemental Material 2. 
Methods 
Sensitivity Analysis. Sensitivity analysis of inhibitory parameter estimates on 
model-predicted peak concentration (Cmax) and systemic exposure (AUC) was 
conducted in Berkeley Madonna. Parameters representing reversible or irreversible 
inhibition of CYP2C9 or CYP3A4/5 were adjusted from ten-fold below to ten-fold above 
the starting parameter (Table 4.1) in half-log increments.  
Figure Legend 
Figure 4.S.1. Sensitivity analysis of probe substrate Cmax and AUC as a function 
of inhibitory kinetic parameters. Symbols denote pharmacokinetic outcomes recovered 
by non-compartmental analysis of simulated concentration-time curves resulting from 
adjusting the inhibitory kinetic parameters. Closed symbols denote reversible inhibition 
parameters. Open symbols denote irreversible inhibition parameters. 
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Chapter 5 
 
Conclusions 
 
Summary and Discussion 
 
Herbal product usage in the United States has increased exponentially in recent 
years as consumers turn increasingly to these products as a means to decrease health 
care costs via self-diagnosis and treatment. The misperception that herbal products are 
safe has perpetuated multibillion dollar sales of these products, exposing the public to 
potentially harmful herb-drug interactions when constituents in the herbal product inhibit 
drug metabolizing enzymes. Since herbal products are not regulated as drug products, 
several regulatory agencies, including the US FDA, do not request information about 
herb-drug interaction (HDI) potential prior to marketing. In addition to limited regulatory 
focus, evaluations of HDI liability are subject to inherent limitations. First, as herbal 
products are derived from natural sources, both between- and within-brand variability 
greatly exceeds that of drug products. Second, herbal products are complex mixtures of 
bioactive constituents, and the inhibitory constituent(s) responsible for the interaction 
often are not identified. Third, because herbal products are self-administered, standard 
dosing regimens are nonexistent. These inherent challenges can be addressed by 
determining requisite kinetic parameters from individual herbal product constituents and 
incorporating into physiologically-based pharmacokinetic (PBPK) interaction models.  
The overall goal of this dissertation research was to evaluate the HDI potential of 
the exemplar herbal product milk thistle using PBPK modeling techniques. The global 
hypothesis was that integration of in vitro inhibitory kinetic parameters of individual milk 
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thistle constituents into a PBPK interaction model would permit more accurate 
predictions of herb-drug interactions than traditional static models. The short term goal of 
this project was to improve the understanding of the in vitro-in vivo disconnect regarding 
milk thistle-drug interactions. The long term goal was to improve the design of in vitro 
and clinical herb-drug interaction studies. Subsequent discussion will focus on major 
observations, limitations, and opportunities for future research resulting from this 
dissertation. 
Evaluate milk thistle-drug interaction potential using established in vitro systems. 
The inhibitory potential of individual milk thistle constituents toward CYP2C9 
(Chapter 2, Appendix A) and CYP3A4/5 (Chapter 3) were evaluated using standard in 
vitro assays of CYP activity. Individual flavonolignans differentially inhibited both 
CYP2C9 and CYP3A4/5, with no apparent correlation in inhibitory potency between the 
two enzymes. Initial evaluation identified silybin A and silybin B as potent inhibitors of 
CYP2C9 activity (Ki = 10 and 4.8 μM, respectively) (Chapter 2), with subsequent 
evaluation highlighting the potency of silychristin and silydianin (Appendix A). In contrast 
to low inhibitory potency (<25% inhibition at 100 µM) towards CYP2C9, the relatively 
less abundant constituents isosilybin A and isosilybin B were two of the more potent 
inhibitors of CYP3A4/5 activity. The crude extract silymarin, rather than single 
constituents, was consistently one of the most potent inhibitors of CYP2C9 (Appendix A) 
and CYP3A4/5 (Chapter 3) activity in microsomal preparations. In an attempt to 
elucidate the mechanism underlying the increased potency of silymarin, an “artificial” 
silymarin preparation was generated (Appendix B), which contained all flavonolignans 
and the sole flavonoid, but lacked fatty acids and other polyphenolic compounds. 
Comparison of the IC50 of the commercial and artificial silymarin preparations 
demonstrated a roughly three-fold increase in potency when fatty acids/other 
polyphenolic compounds were included (Appendix B). Taken together, the net effect of 
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the fatty acids and other polyphenolic compounds in the commercial preparation is to 
increase the inhibitory potency of silymarin. This apparent increase could be due to 
direct inhibition of CYP3A4/5 by fatty acids and/or other polyphenolic compounds. 
Alternatively, the fatty acids/other polyphenolic compounds could inhibit CYP3A4/5 
activity indirectly by synergistic inhibition with flavonolignans or by increasing the 
solubility of inhibitory flavonolignans. Identification and quantification of the fatty acids 
and/or polyphenolic compounds would facilitate evaluation of direct modulation of CYP 
activity. Without this information, incubations with human serum albumin may allow 
indirect assessment of the interaction potential of adulterant compounds. In theory, 
albumin will sequester the fatty acid fraction of silymarin and abrogate the increased 
potency towards CYP activity (Rowland et al., 2008; Wattanachai et al., 2012). Milk 
thistle flavonolignans have poor water solubility but are believed to be soluble at 
concentrations approaching 200 µM when solvents such as DMSO (0.1% v/v final 
concentration) are used. Solubility measurements with and without fatty acids can be 
used to assess the likelihood of solubility enhancement when the fatty acids are present. 
Administration of 420 mg/day silymarin for 14 days was associated with an increase 
in the systemic exposure of the CYP2C9/3A substrate losartan (Han et al., 2009), 
whereas administration of 1.4 g/day silibinin for 7 days had no effect on (S)-warfarin 
exposure (Chapter 4). In addition to the theories posited in Chapter 4, another 
explanation for this discrepancy is that one of the constituents in silymarin (but not 
silibinin) yet to be identified and fully characterized is a potent inhibitor of CYP2C9. 
Based on preliminary results (Appendix A), the constituents silychristin and silydianin 
should be evaluated as additional inhibitors of CYP2C9 using methods described in 
Chapters 2 and 3. Potent reversible or mechanism-based inhibition of CYP2C9 by these 
constituents would help to explain these inconsistent clinical drug interactions with milk 
thistle preparations and compel clinical evaluation.      
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Although the current work focused on cytochromes P450 2C9 and 3A4/5, milk thistle 
constituents may also modulate the activity of other drug metabolizing enzymes. Usage 
of milk thistle products has increased over the last decade among cancer patients, in 
part as a means to decrease chemotherapeutic agent-induced liver damage. The 
clearance of several chemotherapeutic agents, including paclitaxel (CYP2C8), tamoxifen 
(CYP2D6), and irinotecan (UGT1A1), are sensitive to modulations in activity of a single 
enzyme. Subsequent analysis of milk thistle interaction potential should prioritize 
enzymes such as CYP2C8, CYP2D6, and UGT1A1, for which serious adverse events 
could be expected with co-administration of milk thistle products and chemotherapeutic 
agents. While cancer patients, due to high milk thistle usage rates, are likely candidates 
for adverse events with milk thistle products, myriad additional drugs are sensitive to 
inhibition of a single enzyme. For this reason, the milk thistle interaction potential with 
other important drug metabolizing enzymes should be evaluated. Interaction potential 
assessment of milk thistle constituents towards the aforementioned enzymes can be 
conducted according to the framework described in Chapters 2 and 3. 
Methylated analogs of silybin B were developed as a means to decrease metabolic 
lability in vivo and to determine the chemical moieties key for biologic activity in vitro (Sy-
Cordero et al., 2013). Evaluation of these compounds as inhibitors of CYP2C9 activity 
demonstrated either increased or decreased inhibitory potency depending on the site 
and extent of methylation (Appendix A). Continued selective modification of milk thistle 
constituents can help determine the key regions for inhibition of CYP activity, as well as 
sites of metabolism. Although indirect evidence suggests that the 1-4 dioxane moiety of 
silybin A and silybin B is responsible for the mechanism-based inhibition (MBI) of 
CYP3A4, MBI from this moiety has not been demonstrated directly. Selective 
halogenation of this moiety theoretically could prevent oxidation and abrogate CYP3A4 
inactivation. In addition to mechanistic information regarding the site of oxidation 
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resulting in CYP3A4 inactivation, selective modification of milk thistle flavonolignans may 
prevent oxidative or conjugative metabolism. The resultant decreased clearance could 
increase bioavailability and potentially lead to increased pharmacologic action. 
Following oral administration of a milk thistle preparation, individual constituents are 
metabolized rapidly, with the resultant conjugated metabolites achieving systemic 
concentrations much higher than parent compounds. Despite this increase in systemic 
exposure, knowledge regarding the pharmacologic activity or interaction potential of 
these metabolites is limited. Comprehensive evaluation of the interaction potential of 
milk thistle preparations requires testing of the metabolites in addition to the parent 
compounds. To date, difficulties in the isolation and purification of the conjugated 
metabolites have hampered evaluation of these compounds. Future emphasis on these 
processes should produce sufficient quantities of the metabolites to support evaluation 
of drug interaction liability according to the framework discussed in Chapters 2 and 3.    
Despite demonstrating MBI with recombinant CYP3A4 and a positive signal in an 
IC50 shift assay with both recombinant CYP3A4 and human microsomes (Chapter 3), 
silybin A and silibinin demonstrated no discernible MBI with microsomal preparations 
(Appendix C). Recombinant CYP3A4 was markedly more sensitive to MBI in the IC50 
shift assays (Chapter 3), indicating that differences in the enzyme preparation may 
influence the positive predictive value of the test system. To elucidate fully the 
interaction potential of milk thistle constituents, the discrepant extent of MBI should be 
investigated. Initial evaluation should focus on absolute identification of MBI with 
recombinant enzymes. Identification of a compound as a mechanism-based inhibitor 
requires meeting several experimental criteria: time-dependent inactivation, saturation of 
inactivation, substrate protection, irreversibility, inactivator stoichiometry, involvement of 
a catalytic step, and inactivation prior to release of active species (Silverman and Daniel, 
1995). The current experiments have demonstrated time-dependent and saturable 
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inactivation with recombinant CYP3A4 and inactivation prior to the release of active 
species (Chapter 3). However, true irreversibility and substrate protection have not been 
assessed. Following incubation of milk thistle constituents and recombinant enzymes, 
addition of potassium ferricyanide or dialysis of ‘inactivated’ enzyme will differentiate 
time-dependent from mechanism-based inhibition. Addition of other CYP3A4/5 
substrates such as testosterone, alprazolam, or nifedipine may mitigate CYP3A4/5 
inactivation through a process termed ‘substrate protection’. As the inhibitor and 
substrate should bind to the active site of the enzyme, the additional substrate will inhibit 
competitively the inhibitor binding and result in decreased enzyme inactivation. Following 
identification of a constituent as an MBI of recombinant CYP3A4, subsequent 
experiments with microsomal preparations should focus on higher concentrations of the 
MBI. As the observed KI with recombinant enzymes is roughly 100 µM, concentrations 
approaching 200 µM should be evaluated.  
Milk thistle constituents have been established to undergo rapid conjugation 
following oral administration; however, the rates and extents of these metabolic 
processes have not been determined. Likewise, the rate and extent of protein-mediated 
flux of these compounds has not been reported. Whereas conventional pharmaceutical 
agents undergo rigorous reaction phenotyping to identify the enzymes and transporters 
important for distribution or clearance, natural products generally are not subjected to 
such testing. Elucidation of distributional and metabolic parameters would facilitate 
estimations of drug interaction liability by accurately reflecting concentrations in the 
relevant tissues (typically liver and intestine), as well as reflecting the duration of 
exposure. Since the compounds are cleared mainly by UGTs, the first priority should be 
to determine the enzyme kinetic parameters of conjugation in microsomal preparations 
and recombinant UGTs. Scarcity of authentic standards may necessitate measuring 
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substrate loss initially, but advances in analytical methods (Kren et al., 2000) should 
facilitate generation of glucuronide standards and measurement of metabolite formation.  
In addition to metabolic clearance, transport-mediated distribution of milk thistle 
constituents should be evaluated. Milk thistle preparations and individual constituents 
have been tested as inhibitors of transport-mediated flux (reviewed in Chapter 1); 
however, no study to date has focused on these constituents as substrates of 
transporters. Uptake kinetics for milk thistle constituents can be determined by 
measuring accumulation in suspended hepatocytes or mammalian cell lines such as 
human embryonic kidney (HEK) or Madin-Darby canine kidney (MDCK) cells that have 
been transfected with human transporters (Cvetkovic et al., 1999; Cui et al., 2001; Kindla 
et al., 2011; Kimoto et al., 2013; Köck et al., 2013). The methods for such experiments 
can be adopted from previously published studies determining the extent of uptake 
transporter inhibition by silymarin or milk thistle constituents as reviewed in Chapter 1. 
Efflux kinetics may be determined via experiments with sandwich-cultured hepatocytes, 
inside-out membrane vesicles, or Caco-2 cells (Liu et al., 1999; Wheeler et al., 2000; 
Annaert et al., 2001; Troutman and Thakker, 2003; Hemauer et al., 2010). Milk thistle 
constituents are rapidly conjugated in systems with functioning drug metabolizing 
enzymes, making the membrane vesicles the ‘cleaner’ system for initial evaluation. 
Inhibition of UGTs in the other cell systems with the prototypic inhibitors diclofenac or 
quercetin may remove the potential confounding metabolism. 
Predict the clinical impact of silymarin co-administration with prototypic 
cytochrome P450 probe substrates. 
 A PBPK modeling and simulation approach was utilized to predict the clinical 
impact of milk thistle co-administration with the CYP probe substrates warfarin 
(CYP2C9) and midazolam (CYP3A4/5). As discussed in Chapter 4, the PBPK model 
accurately described the distribution and clearance of the probe substrates. Further 
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refinement of the warfarin model should incorporate in vitro metabolic clearance 
parameters to eliminate the need to fit the model to existing clinical concentration-time 
data. Further evaluation of the midazolam model should incorporate intravenous dosing 
to ensure that the hepatic clearance and volume of distribution are reflected accurately 
in the model. The current midazolam model assumes complete metabolic clearance of 
midazolam by CYP3A4/5. Incorporation of alternate pathways such as 4-hydroxylation, 
N-glucuronidation, and renal elimination will minimize potential overpredictions of 
interaction potential (Klieber et al., 2008; Yang et al., 2012).  
 PBPK modeling and simulation are limited, in part, due to the vast number of 
parameters necessary for accurate depictions of the complex biologic systems involved 
in the distribution and elimination of compounds. Compound-independent parameters 
such as physiologic blood flows and organ volumes are well-established in the literature 
(Brown et al., 1997; Boecker, 2003). Methods to predict partition coefficients are 
accurate for drug-like molecules but may begin to demonstrate bias and imprecision for 
compounds that deviate from the conventional pharmaceutical chemical space (Poulin 
and Theil, 2000; Rodgers and Rowland, 2007). Although the partition coefficients 
computed for milk thistle constituents likely are reasonable approximations, further 
model refinement should incorporate partition coefficients derived from rodent or human 
tissue to ensure accuracy. Incorporation of clearance and transport kinetic parameters 
derived from in vitro systems also can improve model predictions for silybin A and silybin 
B. The systemic exposure of a selected milk thistle preparation, silibinin, was reflected 
accurately by the current PBPK model. Incorporation of additional milk thistle 
constituents will allow modeling and simulation of other preparations, such as silymarin. 
The majority of existing research has focused on silymarin or milk thistle extract, 
underscoring the necessity to expand the current model to incorporate additional milk 
thistle constituents.   
143 
 
 In addition to addressing challenges inherent to investigations of herbal product 
drug interaction liability, PBPK modeling and simulation can address other complex 
clinical scenarios. Milk thistle-drug interactions caused by reversible inhibition of drug 
metabolizing enzymes and transporters potentially can be minimized by offsetting the 
administration of milk thistle products and sensitive substrates. The dynamic nature of 
PBPK models can be used to determine a dosing regimen that would minimize this 
interaction liability. Simulations of trials in special populations can be facilitated through 
incorporation of relevant physiologic parameters obtained from the literature. 
Prospective simulation of herb-drug interactions in patient populations can determine the 
interaction liability without placing such patients into potentially harmful situations. 
Genetic polymorphisms in relevant drug metabolizing enzymes and transporters also 
can be incorporated into PBPK models to determine the mechanistic consequences of 
such polymorphisms. Incorporation of multiple interaction mechanisms may more 
accurately reflect the complex biological systems involved in the distribution and 
clearance of both victim and perpetrator compounds and may allow more accurate 
predictions of drug interactions involving substrates that have more than one clearance 
pathway.  
Evaluate PBPK model predictions using a proof-of-concept clinical study. 
As predicted from the PBPK modeling and simulation, the geometric mean 
effects of high-‘dose’ silibinin on the pharmacokinetics of (S)-warfarin and midazolam 
were minimal. Although geometric mean (S)-warfarin exposure did not increase 
markedly, three of the twelve subjects experienced more than a 33% increase in 
systemic exposure. Increases of this magnitude for substrates with a narrow therapeutic 
index such as warfarin could lead to adverse events. Accordingly, the CYP2C9 
interaction potential of silibinin cannot be disregarded completely. The systemic 
exposure of midazolam was increased markedly (>33%) in only one subject. 
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Subsequent analysis indicated that the increase in systemic exposure in that subject 
likely was due to markedly lower-than-average exposure at baseline, consistent with 
taking an inducing agent, rather than to an increase in exposure mediated by silibinin. 
Taken together, the interaction liability of silibinin and midazolam likely is minimal. 
However, interactions between silibinin and other sensitive substrates, such as 
simvastatin and nifedipine, or narrow therapeutic index drugs, such as the 
immunosuppressants cyclosporine, tacrolimus, and sirolimus, cannot be excluded.   
 Future clinical evaluation of herb-drug interactions should be predicated upon 
compelling results from the aforementioned future directions. For example, the inhibitory 
potency of silibinin toward UGT1A1 (Chapter 1) indicated potential for interactions with 
sensitive substrates such as ezetimibe and raloxifene. Other drug metabolizing 
enzymes, transporters, and alternate trial design strategies can be employed to evaluate 
the utility of the newly developed PBPK models. Ultimately, pharmacodynamic endpoints 
(e.g., pupil diameter as a measure of opiate-like central nervous system effects) can be 
approximated to allow pharmacodynamic-based clinical studies.   
Significance 
 This dissertation project developed novel translational methods to predict, 
quantitatively, metabolic herb-drug interactions using milk thistle as an exemplar herbal 
product. Integration of in vitro-derived inhibitory kinetic parameters and estimates of 
systemic exposure to individual constituents into a PBPK interaction model facilitated 
accurate predictions of the lack of interaction between silibinin and the probe substrates 
warfarin and midazolam. Application of these methods could facilitate regulatory 
guidelines by providing a framework for systematic evaluation of herb-drug interaction 
liability that can be used prospectively. Clinically relevant herb-drug interactions, as 
identified by these methods, can impact label changes of sensitive victim drugs. 
Translation of bench-top scientific information to clinical practice will facilitate the 
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identification and management of herb-drug interactions, ultimately promoting safe co-
administration of herbal products and conventional pharmacotherapies.   
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Appendix A: Inhibition of CYP2C9 by milk thistle constituents and silybin B methylation 
products1,2 
 
Materials and Methods 
Chemicals and reagents. Common reagents were procured as described in 
Chapter 2. Milk thistle constituents were isolated as described previously (Graf et al., 
2007). Methylated analogues of silybin B (Compound 1) were prepared according to 
published methods (Dzubak et al., 2006). Briefly, dimethyl sulfate was added to a 
solution of silybin B and potassium carbonate in anhydrous acetone. The mixture was 
heated at reflux for 30 min, cooled to room temperature, acidified with dilute hydrochloric 
acid, and extracted with ethyl acetate. The organic extracts were combined and 
concentrated to dryness under reduced pressure. The resulting oil was purified using 
RP-HPLC to yield five major products (Figure A.1) in greater than 95% purity as 
measured by analytical RP-HPLC. 
Evaluation of milk thistle constituents and methylated analogues as 
inhibitors of CYP2C9. The inhibitory effects of milk thistle constituents and silybin B 
methylated analogues were evaluated as described in Chapter 2. 
Results 
Milk thistle constituents differentially inhibit CYP2C9 activity. The potency of 
the milk thistle constituents and crude extract not tested previously (Chapter 2) was 
evaluated against CYP2C9 activity ((S)-warfarin 7-hydroxylation). Silychristin and 
silymarin inhibited CYP2C9 activity in a concentration-dependent manner (1 vs. 10 µM) 
(Figure A.2). When tested at 100 µM, both preparations inhibited activity to levels below 
the lower limit of quantitation. Isosilychristin and silydianin inhibited activity in a 
                                               
1
 A. A. Sy-Cordero et al. Bioorg. Med. Chem. 21 (2013) 742–747 
 
2 Reprinted with permission from Elsevier. 
 
149 
 
concentration-dependent manner from 10 to 100 μM but not from 1 to 10 µM. Activity 
was reduced by at least 50% when incubated with all constituents at 100 µM. 
Methylation of silybin B impacts inhibitory potency toward CYP2C9 activity. 
The CYP2C9 inhibitory potencies of the methylated analogues (2–5) were compared 
(Fig. A.3); compound 6 was not evaluated due to paucity of sample. With the exception 
of 5, all compounds inhibited CYP2C9 activity in a concentration-dependent manner (1 
vs 10 µM). Compound 2 was less potent than 1 at 100 µM, whereas compounds 3 and 
4, representing monomethylation at the 7-OH and dimethylation at the 7- and 400-OH 
moieties, respectively, were more potent than 1, with activities below the limit of 
quantification when tested at 100 µM.  
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Legends to Figures  
Figure A.1. Chemical structures of silybin B and methylated analogues. 
Figure A.2. Effects of silymarin and milk thistle constituents on CYP2C9-mediated (S)-
warfarin 7-hydroxylation in human liver microsomes (HLM). Incubation mixtures 
consisted of HLM (0.1 mg/mL), (S)-warfarin (4 µM), silybin B or methylated analogue (1, 
10, or 100 µM; open, solid, and hatched bars, respectively) and potassium phosphate 
buffer (100 mM, pH 7.4). Reactions were initiated by the addition of NADPH (1 mM) and 
were terminated after 30 min with ice-cold MeOH (2 volumes). Activity in the presence of 
vehicle control (0.75% MeOH, v/v) was 4.3 ± 0.26 pmol/min/mg microsomal protein. 
Bars and error bars denote means and SDs, respectively, of triplicate incubations. BLQ, 
below limit of quantification. *p<0.05, 1 versus 10 µM; #p <0.05, 10 versus 100 µM (two-
way ANOVA followed by Tukey’s test). 
Figure A.3. Effects of silybin B (1) and methylated analogues (2–5) on CYP2C9-
mediated (S)-warfarin 7-hydroxylation in human liver microsomes (HLM). Incubation 
mixtures consisted of HLM (0.1 mg/mL), (S)-warfarin (4 µM), silybin B or methylated 
analogue (1, 10, or 100 µM; open, solid, and hatched bars, respectively) and potassium 
phosphate buffer (100 mM, pH 7.4). Reactions were initiated by the addition of NADPH 
(1 mM) and were terminated after 30 min with ice-cold MeOH (2 volumes). Activity in the 
presence of vehicle control (0.75% MeOH, v/v) was 4.3 ± 0.26 pmol/min/mg microsomal 
protein. Bars and error bars denote means and SDs, respectively, of triplicate 
incubations. BLQ, below limit of quantification. *p<0.05, 1 versus 10 µM; #p <0.05, 10 
versus 100 µM; †p <0.05 versus silybin B at 100 µM (two-way ANOVA followed by 
Tukey’s test). 
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Appendix B. Evaluation of the inhibitory potency of a commercial silymarin preparation 
and an artificial preparation towards CYP3A activity. 
 
Materials and Methods 
Chemicals and reagents. Common reagents were procured as described in 
Chapter 3. Commercial preparation of silymarin was obtained from the Rottapharm 
Madaus subsidiary Euromed S.A. (Barcelona, Spain). Artificial silymarin was produced 
by combining individual milk thistle constituents (Graf et al., 2007) in the respective 
abundance of the commercial silymarin preparation (Davis-Searles et al., 2005) (Figure 
B.1). The composition of artificial silymarin should mirror that of commercial silymarin 
with respect to the flavonolignans and flavonoid but lack the fatty acids.  
Evaluation of milk thistle constituents and methylated analogues as 
inhibitors of CYP3A4/5. The inhibitory effects of artificial and commercial silymarin 
were evaluated as described in Chapter 3, with the addition of a single donor human 
intestinal microsomal preparation (HI-5 J7). 
Results 
Silymarin preparations differentially inhibit CYP3A4/5 activity. Artificial 
silymarin was a more potent inhibitor of CYP3A4/5 mediated midazolam 1’-hydroxylation 
in all enzyme preparations (Figure B.2). This increased potency was reflected in a 
roughly 3-fold increase in IC50 following the “removal” of the fatty acid fraction of 
silymarin (Table B.1). The inhibitory potencies of commercial and artificial silymarin were 
similar between enzyme preparations. 
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Legends to Figures  
 
Figure B.1. Relative composition of the commercial silymarin product. 
 
Figure B.2. Inhibitory effects of commercial and artificial silymarin preparations on 
midazolam 1’-hydroxylation activity in pooled human liver microsomes (A), pooled 
human intestinal microsomes (B), and single donor human intestinal microsomes (D). 
Microsomes (0.05 mg/mL) were incubated with midazolam (4 µM) and silymarin 
preparation (0-200 µM) for 2 (liver microsomes) or 4 (intestinal microsmes) min. 
Reactions were initiated with NADPH (1 mM). Midazolam 1’-hydroxylation activity in the 
presence of vehicle control [0.1% (v/v) DMSO] was 1900 ± 170, 440 ± 34, or 1460 ± 65 
pmol/min/mg microsomal protein for human liver microsomes, pooled human intestinal 
microsomes, and single donor human intestinal microsomes, respectively. Symbols and 
error bars denote means and SDs, respectively, of triplicate incubations. Solid and 
dashed curves denote nonlinear least-squares regression of observed data using 
WinNonlin (version 5.3)  
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Table B.1. Comparison of IC50s
a (µM) for Commercial (CS) and Artificial (AS) silymarin in 
human liver microsomes (HLM), pooled human intestinal microsomes (pHIM), and 
single-donor human intestinal microsomes (iHIM).  
Microsomes CS AS p-valueb 
HLM 41 ± 5.0 130 ± 15 0.005 
pHIM 46 ± 6.8 130 ± 12 0.004 
iHIM 63 ± 6.6 160 ± 17 0.006 
aEstimates ± SEs; bCS vs. AS, Student’s t-test 
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Appendix C: Mechanism-based inhibition of CYP3A4/5 activity  
in microsomal preparations 
Methods 
Chemicals and reagents. All chemicals and reagents were procured as 
described in Chapter 3.  
Determination of mechanism-based inhibition kinetics. Time- and 
concentration-dependent inhibition of CYP3A4 was assessed as described previously 
(Paine et al., 2004) and detailed in Chapter 3. Briefly, primary incubation mixtures 
consisting of HLM or HIM, milk thistle constituent/extract (0-100 μM), and potassium 
phosphate buffer were equilibrated at 37°C for 5 min before initiating the primary 
reactions with NADPH. As a positive control for mechanism-based inhibition, reaction 
mixtures contained 5 μM DHB in place of milk thistle constituent/extract. At designated 
time points (0-15 min), an aliquot (4 μL) was removed and diluted 50-fold into a 
secondary reaction mixture containing midazolam (8 μM) and NADPH (1 mM). The 
secondary reactions were terminated and processed as described for the reversible 
inhibition experiments. 
Results 
Silybin A and Silibinin Do Not Demonstrate Mechanism-Based Inhibition of 
CYP3A Activity.  The time- and concentration-dependent inhibition of CYP3A4/5 activity 
by silybin A and silibinin was determined to derive mechanism-based inhibition inhibitory 
kinetics. Unlike with rCYP3A4 (Chapter 3), neither silybin A (Fig. C.1A,C and Fig. C.2A) 
nor silibinin (Fig. C.1B,D and Fig. C.2B) demonstrated time-dependent inhibition of 
CYP3A4/5 activity.  
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Legends to Figures  
Figure C.1. Time- and concentration-dependent inhibition plot of CYP3A4/5 activity. 
Human liver (A, B) or intestinal microsomes (C, D) were incubated with silybin A (A,C) 
and silibinin (B,D) (0-100 µM). The primary reaction mixture was diluted 50-fold to initiate 
the secondary reaction, which contained NADPH (1 mM) and midazolam (8 µM), at 
designated times. Symbols denote means of duplicate incubations. As a positive control 
for mechanism-based inhibition, reaction mixtures contained 5 μM DHB in place of 
silybin A/silibinin.   
Figure C.2. Time- and concentration-dependent inhibition plot of CYP3A4/5 activity. 
Human liver microsomes were incubated with silybin A (A) and silibinin (B) (0-100 µM). 
The primary reaction mixture was diluted 5-fold to initiate the secondary reaction, which 
contained NADPH (1 mM) and midazolam (8 µM), at designated times. Symbols denote 
means of duplicate incubations. As a positive control for mechanism-based inhibition, 
reaction mixtures contained 5 μM DHB in place of silybin A/silibinin.   
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